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ABSTRACT

With Fluorescence Resonance Energy Transfer (FRET), we are able to detect
changes in the structure and affinity of the PLB-SERCA regulatory complex in live cells.
Using this approach, we have detected a high level of PLB-SERCA interaction even at
Ca2+ concentrations known to fully relieve PLB inhibition of SERCA, suggesting that
dissociation is not required for relief of inhibition. We also detect no real-time change
in PLB-SERCA binding over the course of a single Ca2+ transient in paced myocytes. The
effect of Ca2+ on the PLB-SERCA interaction is best described as a reduced affinity with
no change in the structure of the complex. Even though we do not observe a change in
the structure of the PLB-SERCA complex with changes in calcium concentrations, we
currently hypothesize that the reduced affinity is produced by a transition of PLB into an
alternative binding site. We propose that the transmembrane domain of PLB could
move independently of its cytosolic domain. Our fluorescent probe is attached to the
cytosolic domain of PLB, which would explain our inability to detect a change in the
position of the transmembrane domain. My current work attempts to address this by
measuring the FRET between SERCA and a truncated PLB lacking the cytosolic domain.

x

CHAPTER I

INTRODUCTION

The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) is a responsible for
maintaining the Ca2+ gradient across the membrane of intracellular vesicles of all cells
(MacLennan & Kranias, 2003). This process is of particular importance in muscle cells in
which Ca2+ triggers contraction by binding troponin C, allowing myosin-actin crossbridge
formation (Gordon, Homsher, & Regnier, 2000). SERCA is responsible for decreasing
cytosolic Ca2+ concentrations necessary for muscle relaxation as well as loading the SR
with Ca2+ necessary for further release events (Bers, 2008). SERCA is believed to
function through a series of coordinated structure changes mediated through the
binding of Ca2+ and ATP and subsequent hydrolysis of ATP (MacLennan, Toyofuku, &
Lytton, 1992; Toyoshima & Inesi, 2004).

The two primary generalized structural

conformations of SERCA are described as the Ca2+ bound state, E1, and Ca2+ unbound
state, E2. The continual beating of the heart requires almost constant SERCA activity,
meaning proper function and regulation is of the utmost importance in the survival of
the heart.
In cardiac tissue, phospholamban (PLB) is the primary regulator of SERCA
activity, and has been shown to bind to and inhibit the activity of SERCA (MacLennan &
Kranias, 2003). This inhibition is achieved by decreasing the apparent affinity of Ca2+ for
1

2
SERCA. In other words, higher concentrations of Ca2+ are required to the same levels of
activity that occur in the absence of PLB. Therefore, Ca2+ can overcome in the inhibition
of SERCA by PLB, but the mechanism for this relief of inhibition remains unclear. PLB is
a key target of β-adrenergic signaling with phosphorylation partially relieving the
inhibition of SERCA. Its name is derived from the Greek words for “phosphate” and “to
receive.”
A general depiction of Ca2+ handling in cardiac myocytes is depicted in Fig. 1
(Bers, 2008). Membrane depolarization causes the opening of L-type Ca2+ channels,
causing an influx of Ca2+ and resulting in a Ca2+-induced Ca2+ release from the
sarcoplasmic reticulum (SR) through the ryanodine receptor. Ca2+ accumulates in the
cytosol, triggering muscle contraction.

SERCA is responsible for pumping the

accumulated Ca2+ back into the SR, reducing cytosolic concentrations and loading the SR
with Ca2+ for future release. PLB can inhibit SERCA, modulating Ca2+ movement.
Two basic models have been used to explain the mechanism by which Ca2+
overcomes the inhibition by PLB. For the sake of discussion, I will refer to them as the
“Dissociation Model” and the “Subunit Model.” The Dissociation Model suggests that
PLB stabilizes a structural conformation of SERCA, thereby preventing its transition to an
alternative conformation capable of binding Ca2+. Ca2+ essentially competes with PLB
for binding to SERCA. Therefore, PLB must be displaced from SERCA for Ca2+ to bind and
the pumping cycle to proceed. The Subunit Model suggests that PLB merely slows the

3

Figure 1: Diagram of the basic calcium handling elements within cardiac myocytes.
Membrane depolarization opens L-Type calcium channels initiating a calcium induced
calcium release by the ryanadine receptor (RyR), elevating cytosolic calcium
concentrations. This cytosolic calcium is then pumped back into the SR against its
concentration gradient via SERCA, the activity of which can be inhibited by PLB.
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on-rate of Ca2+, allowing the possibility that PLB can remain bound to SERCA throughout
its reaction cycle. Both models appear to be incomplete and do not account all data in
field. The primary goal of this dissertation is to address these inconsistencies and
propose an alternative, more inclusive model which we have named the “Domain
Displacement Model.”
In this dissertation, I will propose that PLB has an alternative binding site on
SERCA and that the binding of Ca2+ displaces PLB to this site rather than preventing any
interaction. This model is supported through my research as well as evidence from the
Na, K-ATPase and its regulator phospholemman, a protein system highly homologous to
PLB-SERCA. This is also supported by previously published work by our lab showing that
phosphorylated PLB can still bind SERCA. This model challenges the general concept
that relief of inhibition requires dissociation, but is not in conflict with the previous
research in the field.
Much of our understanding of SERCA function comes from steady state
biochemical assays.

However, the contracting heart is by no means a steady state

environment, especially with respect to Ca2+. Ca2+ concentration is oscillating on a beatto-beat basis facilitating contraction and relaxation. One of the primary questions of
this dissertation is how PLB interacts with SERCA over the course of a single Ca2+
transient. Can the elevated Ca2+ from a single transient overcome the PLB inhibition of
SERCA? Or can the effect of elevated Ca2+ integrate over time?

5
The biochemical steps of SERCA activity have been well understood since the
1970’s.

With the more recent detailed structural information coming from

crystallographic studies, SERCA has provided a unique venue in the study of the
structure-function relationship of complex proteins. In this dissertation, I will address
how PLB is able to interact with various structural conformations of SERCA.
This dissertation will first start with a review of literature describing SERCA and
PLB themselves as well our current understanding of the regulatory mechanism. I will
then address the conflicting approaches used to assess the PLB-SERCA interaction. I will
then discuss how disregulation of SERCA can be involved in disease to underscore the
importance of this functional interaction.
In the next section I will discuss the materials and methods employed for this
dissertation. This will be followed by a description of an in cell SERCA activity assay
which we developed to test the functionality of our fusion proteins. The next section
addresses the steady-state nature of the PLB-SERCA interaction addressing how PLB
interacts with SERCA in various conformational steps. In chapter VI, I show my research
that directly tests our newly proposed model of PLB-SERCA interaction. In chapter VII, I
attempt to show the dynamic nature of the PLB-SERCA interaction by making real-time
measurements. Finally, I will discuss the broader implications of my research and how
my results integrate with the findings of others.
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I would also like to note that the bulk of work shown in sections IV, V and VII was
published this past October in the Journal of Biological Chemistry (Bidwell, Blackwell,
Hou, Zima, & Robia, 2011).

CHAPTER II

REVIEW OF RELATED LITERATURE

SERCA
P-type Ion Pumps

SERCA belongs to the P-type pump family of ATPases (Kühlbrandt, 2004;
Wuytack, Raeymaekers, & Missiaen, 2002).

P-type pumps utilize ATP hydrolysis to

undergo a series of structural transitions, producing a reversibly phosphorylated state,
from which the family name is derived. Most family members have 10 transmembrane
helices (M1-10), though the greatest variation between members occurs in the
transmembrane region, which determines ion specificity.
The family also shares three cytosolic or headpiece domains, the most
homologous region in the family (Kühlbrandt, 2004; Wuytack et al., 2002). They are
commonly called the N, P, and A domains (Nucleotide, Phosphorylation, and Actuator).
The ATP binding site is located on the N-domain. A conserved lysine is an integral
component of the nucleotide binding site. The gamma-phosphate of that ATP is then
transferred to an aspartate in a conserved motif, DKTGTLT, on the P-domain. The Pdomain is also the most highly conserved domain within the family. The P-domain is
also homologous to a class of bacterial enzymes demonstrating its general biochemical
role and importance.
7
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SERCA Isoforms
In vertebrates, 3 distinct genes encode for SERCA that produce at least 10
different isoforms through alternative splicing (Periasamy & Kalyanasundaram, 2007;
Wuytack et al., 2002). SERCA2b is the “housekeeping” isoform found in all cells, at least
at some low level. SERCA2a is the predominant isoform found in cardiac muscle and
slow twitch skeletal muscle. SERCA1a is expressed in adult fast twitch skeletal muscle
and has been the most highly studied isoform because of its abundance in and ease of
collection from animal tissue. There are 6 SERCA3 isoforms (a-f) found in various
tissues, with a, d, and f found at low levels in cardiac tissue. SERCA2a and SERCA1a are
84% identical with the SERCA3 isoforms being roughly 75% identical to either
SERCA1a/2a. Because of the high degree of homology, all SERCA isoforms are believed
to have almost identical structures. All isoforms are capable of being inhibited by
thapsigargin. SERCA1a and SERCA2a have similar affinities for Ca2+, but SERCA1a has a
faster catalytic velocity. SERCA2b has a higher Ca2+ affinity than either SERCA1a/2a, but
lower catalytic rate.
Reaction Scheme
SERCA activity was first observed when isolated SR membrane was shown to
have ATPase and Ca2+ uptake ability from skeletal muscle (Ebashi & Lipmann, 1962), and
later from cardiac myocytes (Hasselbach & Makinose, 1962).

Evidence of a

phosphorylated protein intermediate during the reaction process provides the first
insight into the mechanism of SERCA function. In 1966, Jardetzkey postulated the

9
simple but still accepted model of ion transport where ions bind with differential affinity
on opposing sides of the membrane (high on the binding or uptake side and low on the
release or discharge side).

This is coupled to a phosphorylation dependent

conformational change closing the binding pocket on one side and opening it on the
other (Jardetzky, 1966).

Landgraf and Inesi were the first to demonstrate a

conformational change of SR protein in response to ATP through EPR spin labeling
(Landgraf & Inesi, 1969). Tanford further proposed that the change in binding pockets
and affinities could occur simultaneously through a simple movement of membrane
helices altering amino acid side chain interactions

that facilitate ion interaction

(Tanford, 1982).
In 1970, Inesi first described a hallmark of SERCA activity, the dependence of
Ca2+ on the rate of ATPase activity. At low concentrations where little Ca2+ is available
to be pumped across the membrane, SERCA activity is low. Increasing Ca2+ increases
SERCA activity up to maximal level. Along with Inesi, many other groups begin to
characterize the stepwise reaction scheme describing the SERCA reaction cycle
(Carvalho, de Souza, & de Meis, 1976; Coan & Inesi, 1976; Hasselbach, 1978; Kanazawa
& Boyer, 1973; de Meis & Vianna, 1979), on which a general consensus is reached by
1979, as depicted in Fig. 2. All steps were shown to be reversible, providing the
possibility of ATP production. These concepts are still accepted today. A Ca2+ to ATP
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Figure 2: Simplified SERCA reaction diagram. One ATP and two Ca2+ ions bind on the
cytosolic face of the E1 conformation of SERCA, which initiates ATP hydrolysis and
phosphate transfer. The phosphorylated SERCA then readily transitions to the E2
conformation, changing the Ca2+ binding sites from high affinity and cytosolic facing to
low affinity and lumen facing. Ca2+ is then released to the ER/SR lumen, along with the
release of ADP and PI, producing the free E2 conformation.
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stoichiometry of 2:1 was first proposed in 1963 (Hasselbach & Makinose, 1963), but not
clearly described until 1980 (Inesi, Kurzmack, Coan, & Lewis, 1980). In the same study,
Inesi et al also demonstrate the cooperative binding of Ca2+. Spin labeling detected a
structure change after binding of the first Ca2+ ion which is presumed to increase the
binding affinity of the second ion.
SERCA Structure
SERCA was first isolated from rabbit skeletal muscle in 1970 (MacLennan, 1970).
Structural information first came from proteolysis analyses where trypsin digestion of
SERCA produced various fragments and subfragments. ATP and Ca2+ binding could be
associated with these specific fragments. In 1980, partial amino acid sequences were
determined for the cytosolic fragments (Allen, Trinnaman, & Green, 1980). In 1985,
SERCA1a was cloned for the first complete sequence (MacLennan, Brandl, Korczak, &
Green, 1985). The following year SERCA2a was cloned and sequenced (Brandl, Green,
Korczak, & MacLennan, 1986). From these sequences, the MacLennan group deduced
the topology and secondary structure of SERCA, predicting the helical transmembrane
domains and the globular cytosolic domains.
SERCA was first visualized with electron microscopy identifying 40 Å diameter
surface particles on skeletal muscle microsomes (Martonosi, 1968), and later identified
by freeze fracture (Baskin & Deamer, 1969; Deamer & Baskin, 1969). The first low
resolution crystal structure from X-ray diffraction (14 Å) showed a large cytosolic
headpiece attached to a narrow transmembrane region (Toyoshima, Sasabe, & Stokes,
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1993). With enhancement of the resolution to 8 Å, the 10 transmembrane helices could
be visualized and could be associated to the appropriate primary structure sequence
(Zhang, Toyoshima, Yonekura, Green, & Stokes, 1998). After developing conditions
sufficient to grow crystals suitable for X-ray diffraction, a high resolution (2.6 Å)
structure was determined capable of resolving the 3 cytosolic domains (Toyoshima,
Nakasako, Nomura, & Ogawa, 2000). High resolution structures have subsequently
been determined under a variety of conditions and have been associated with
intermediate conformations of SERCA (Toyoshima & Inesi, 2004; Toyoshima & Nomura,
2002). Fig. 3 depicts a few of the proposed intermediate conformations showing
potential large movements of the cytosolic headpiece.
Structure Function Relationship
Integrating the enzymatic and structural data has been a fundamental goal
within the field.

After cloning SERCA, the MacLennan lab performed extensive

mutagenesis studies investigating the role of individual residues (MacLennan, 1990).
Many loss-of-function mutants retained the capability of undergoing partial reactions,
enabling investigation into the particular steps affected by alteration of these residues.
This approach clearly identified Asp351 as the site of phosphoryl transfer (Maruyama et
al., 1989). This approach also lead to the preliminary identification of the Ca2+ binding
sites in the transmembrane region (Clarke et al., 1989; Vilsen, Andersen, Clarke, &
MacLennan, 1989) and of the ATP binding site (Clarke, Loo, & MacLennan, 1990). These
binding sites have been subsequently confirmed by high resolution X-ray crystallography

13

Figure 3: Proposed SERCA structural transitions. SERCA is believed to undergo
conformational transitions upon binding of calcium and ATP, potentially producing large
movements of the cytosolic headpiece. Images represent various crystal structures
produced under conditions thought to be associated with reaction step intermediates.
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(Toyoshima & Inesi, 2004; Toyoshima & Nomura, 2002; Toyoshima et al., 2000). These
studies demonstrate that ATP binding and hydrolysis occur in the cytosolic headpiece far
from the Ca2+ binding sites in the transmembrane region.

Therefore the

transmembrane reorientation necessary for Ca2+ transport is linked to the required
chemical energy through long-range protein interactions.
The various high resolution crystal structures have shown many distinct
conformations of SERCA (Toyoshima & Inesi, 2004; Toyoshima & Nomura, 2002;
Toyoshima et al., 2000). The conditions under which these crystals were produced can
be associated with endpoints of the enzymatic half reactions.

Therefore, these

conformations are thought to correspond to the various enzymatic states of the SERCA
reaction cycle (Fig. 3). Initial results suggested that the stepwise binding of Ca2+ and ATP
induce large scale conformational changes in the cytosolic headpiece domains. These
conformational shifts in the headpiece were thought to produce the mechanical force
necessary to rearrange the transmembrane helices shifting the orientation of the Ca2+
binding sites. However, more recent crystal structures suggest that the structural
changes are much smaller and more subtle than previously believed (Jensen, Sørensen,
Olesen, Møller, & Nissen, 2006; Sørensen, Møller, & Nissen, 2004). This concept of
smaller structural movements is also supported by FRET distance measurements
between probes attached to different cytosolic domains (Winters, Autry, Svensson, &
Thomas, 2008).
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Phospholamban
Discovery
The existence of PLB was first observed with the PKA dependent stimulation of
the ATPase dependent Ca2+ uptake in cardiac SR vesicles (Kirchberger, Tada, Repke, &
Katz, 1972; Tada, Kirchberger, Repke, & Katz, 1974). These vesicles were then shown to
be radiolabeled by P32 upon stimulation by PKA (Kirchberger, Tada, & Katz, 1974). This
radiolabeling was found to be targeted to a 22 kDa protein which was shown to be a
modulator of SERCA (Tada, Kirchberger, & Katz, 1975).

This phosphoprotein was

subsequently termed phospholamban coming from the Greek terms “to receive” and
“phosphate” (Kirchberger, Tada, & Katz, 1975).
This 22 kDa protein was shown to be capable of dissociating into lower
molecular weight components upon boiling or treatment with Triton-X (Jones, Besch,
Fleming, & Mcconnaughey, 1979; Lamers & Stinis, 1980; Le Peuch, Haiech, & Demaille,
1979; Will, Levchenko, Levitsky, Smirnov, & Wollenberger, 1978). Freezing of the
sample was shown to cause reassociation of the lower-molecular weight forms back to
the 22 kDa. These observations suggested that phospholamban could exist as an
oligomer. The lower molecular form was eventually determined to be a 6 kDa peptide
that could be independently phosphorylated by PKA (Bidlack & Shamoo, 1980; Bidlack,
Ambudkar, & Shamoo, 1982).

After improved purification techniques, the high

molecular weight form was shown to be a

30 kDa pentamer of composed of

indistinguishable monomers which could each be independently phosphorylated (Fujii,
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Kadoma, Tada, Toda, & Sakiyama, 1986; Wegener & Jones, 1984; Wegener, Simmerman,
Liepnieks, & Jones, 1986). The full sequence of PLB was determined after it was cloned
by the Tada lab (Fujii et al., 1987).
Structure
PLB is a 52 amino acid integral membrane protein that is comprised of 3
domains, Ia (residues 1-20), Ib (residues 21-30), and II (residues 31-52) (Bhupathy, Babu,
& Periasamy, 2007). Proteolysis studies first suggested the existence of 2 domains, a
protease sensitive cytosolic domain (1a/b) and protease insensitive transmembrane
domain (II) (Wegener et al., 1986). Circular dichroism experiments further suggested
the existence a cytosolic (Ia) and transmembrane (II) alpha helices separated by and
unstructured linker or hinge domain (1b) (Simmerman, Lovelace, & Jones, 1989; Terzi,
Poteur, & Trifilieff, 1992). These observations were consistent with sequence analysis
proposing likely alpha helical and hydrophobic/hydrophilic regions (Fujii et al., 1986,
1987). These observations are also consistent with NMR structures of PLB (Traaseth et
al., 2009) and molecular dynamics simulations (Paterlini & Thomas, 2005).
A fundamental aspect of phospholamban is that it can exist in a monomer as
well as a pentamer (MacLennan & Kranias, 2003; Simmerman & Jones, 1998). The alpha
helical structure of the PLB transmembrane region generates heptad repeats. Because
this pattern, every 3 to 4 residues of the helix align, organizing leucines and isoleucines
along one side or face PLB. Mutagenesis targeting these residues destabilized pentamer
formation whereas mutations along the opposite face of PLB did not alter pentamer
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stability. This suggests that the leucine zipper formation found within the PLB structure
is critical for pentamer assembly (Simmerman, Kobayashi, Autry, & Jones, 1996). This
conclusion has been supported by subsequent NMR studies (Verardi, Shi, Traaseth,
Walsh, & Veglia, 2011). Mutations at 3 cysteines within the transmembrane domain
(residues 36, 41, and 46) have been shown to destabilize PLB pentamer formation (Fujii,
Maruyama, Tada, & MacLennan, 1989), but disulfide linkages were not observed and
are believed be unnecessary for pentamer stability (C. B. Karim, Stamm, Karim, Jones, &
Thomas, 1998; Simmerman, Collins, Theibert, Wegener, & Jones, 1986). Replacement of
cysteines with an isosteric amino acid (α-amin-n-butyric) was shown to have no affect
on pentamer stability (C. B. Karim et al., 2001). This demonstrates that the steric
properties of the cysteines, not their reactivity, contribute pentamer stability.
Because PLB can exist as a pentamer, monomer, and monomer bound to SERCA,
PLB exists in a coupled equilibrium depicted in Fig. 4.

This concept was first

demonstrated when mutations that make PLB more monomeric were shown have
enhanced inhibitory potential and are considered “superinhibitors” (Y Kimura, Asahi,
Kurzydlowski, Tada, & MacLennan, 1998; Y Kimura, Kurzydlowski, Tada, & MacLennan,
1997). These observations are also consistent with work in our lab showing that a
superinhibitory PLB mutant enhances FRET between PLB and SERCA while diminishing
PLB pentamer FRET to an equivalent degree (Kelly, Hou, Bossuyt, Bers, & Robia, 2008).
These studies suggest that themonomer is the active inhibitor of the pump, with the
pentamer being an inactive reservoir, incapable of interacting with SERCA. Through
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Figure 4: Coupled equilibrium of PLB binding. PLB can exist as a pentamer, free
monomer, and monomer bound to SERCA. PLB readily transitions between pentamer
and free monomer (KD1) and between free monomer and monomer bound to SERCA
(KD2). Therefore changes in pentamer binding will alter the binding of PLB to SERCA.
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mass action, changes in pentamer binding will alter binding between PLB and SERCA,
thereby altering the ability of PLB to inhibit SERCA.
X-ray crystal studies have suggested the possibility that the pentamer could
directly interact with SERCA (Stokes, Pomfret, Rice, Glaves, & Young, 2006). However,
this inconsistent with studies from our lab showing a 1:1 stoichiometry in PLB-SERCA
FRET (Kelly et al., 2008). Because this interaction could be an artifact of crystallization,
further study is needed for its validation.
Phosphorylation
PLB is the target of β-adrenergic signaling through PKA phosphorylation of Ser16
and CamKII phosphorylation of Thr17 (Fujii et al., 1989; Simmerman et al., 1986). Thr17
has also been shown be phosphorylated independently of Ser16 in a frequency
dependent manner likely through enhanced CamKII activity (Hagemann et al., 2000;
Mundiña-Weilenmann,

Vittone,

Ortale,

de

Cingolani,

&

Mattiazzi,

1996).

Phosphorylation of Ser16 and Thr17 can occur independently in vitro (Davis, Schwartz,
Samaha, & Kranias, 1983; Jackson & Colyer, 1996; Kranias, 1985). However, during in
vivo studies, phosphorylation of Ser16 appears to be a prerequisite for phosphorylation
of Thr17 through the β-adrenergic pathway (Chu et al., 2000; Luo et al., 1998). Protein
phosphatase-1 (PP1) has been shown to dephosporylate PLB at both sites which
decreases SERCA activity (Kranias & Di Salvo, 1986; MacDougall, Jones, & Cohen, 1991;
Nicolaou, Hajjar, & Kranias, 2009).
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These phosphorylations can independently relieve PLB inhibition of SERCA
thereby enhancing its activity by restoring the Ca2+ sensitivity of SERCA (MacLennan &
Kranias, 2003).

In some early studies, it was suggested that the Ser16 and Thr17

phosphorylations have an additive effect on SERCA activity (Kranias, 1985; Le Peuch et
al., 1979; Raeymaekers, Hofmann, & Casteels, 1988), but these studies do not directly
assess phosphorylation efficiency of their experimental conditions. Further studies
demonstrating full phosphorylation show no additive effect suggesting that the
previously observed additive effect may have been due to incomplete phosphorylation
of PLB (Colyer & Wang, 1991; Jackson & Colyer, 1996).

Mechanism of PLB Inhibition of SERCA
SERCA activity increases with Ca2+ concentration up to a maximum level with a
Hill function relationship (Fig. 5, black). PLB is known to reduce the apparent Ca2+
affinity of SERCA, producing a rightward shift in the SERCA activity curve (Fig. 5, red).
Higher Ca2+ concentrations are then needed to achieve the same levels of activity
observed in the absence of PLB. In other words, increases in Ca2+ concentration can
overcome the inhibition by PLB. Phosphorylation of PLB relieves the inhibition on SERCA
by partially restoring Ca2+ sensitivity, represented as a leftward shift in the SERCA
activity curve (Fig. 5, blue). The process of this relief of inhibition is not fully understood
and is the focus of this dissertation.
SERCA is believed to exist in various conformational states. Early evidence
comes from protein digestion studies, where changes in tertiary structure block or allow
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Figure 5: Simulated example of SERCA activity assay. SERCA activity, which can be
measured by ATPase activity or calcium uptake, increases with increasing cytosolic
calcium concentration in a sigmoidal manner up to a maximal level (black). The
presence of PLB causes a decreased apparent calcium affinity represented by a
rightward shift in the activity curve (red). Higher cytosolic calcium concentrations are
needed to achieve the same SERCA activity. Phosphorylation of PLB shifts this curve
back to left (blue).
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access to cut sites. This approach identified 2 primary SERCA conformations: the E1
Ca2+ bound state and the E2 Ca2+ unbound state. More recent X-ray structures have
been determined for SERCA under various conditions, corresponding to more
conformational states. These conformational states are believed to correspond to
reaction cycle intermediates.
Dissociation Model
The prevailing view favors a model where PLB binds the E2 Ca2+ free state of
SERCA. Interaction with PLB stabilizes this conformation thereby blocking transition to
the E1 conformation by increasing the free energy barrier. Inability to transition to a
conformation capable of binding Ca2+ terminates the reaction cycle of SERCA. PLB must
then completely dissociate from SERCA for transition to occur and activity to be
restored. In this model, binding of PLB and Ca2+ to SERCA is mutually exclusive. I will
refer to this model as the “Dissociation Model” which is depicted in Fig. 6A.
The Dissociation Model is well supported by chemical crosslinking studies from
Jones group. In an initial study, a mutant which introduced a Cys at residue 30 of PLB
(N30C) was coexpressed in insect vesicles (Jones, Cornea, & Chen, 2002). Addition of a
homobifunctional thiol probe, bismaleimidohexane, was shown to chemically crosslink
the introduced Cys of N30C to Cys318 of canine SERCA2a. This demonstrated that
residue 30 of PLB was in close proximity to residue 318 of SERCA. This chemical
crosslinkage could be disrupted through increases in Ca2+ concentration, exhibiting an
EC50 of 130 nM. At high Ca2+ concentrations, crosslinking was completely abolished.
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Figure 6: Models of PLB inhibition of SERCA. (A) The Dissociation Model suggests that
PLB selectively binds the E2 calcium unbound state of SERCA preventing transition to
the E1 conformation capable of binding calcium. PLB must then completely dissociate
from SERCA for function to be restored. (B) The Subunit Model suggests that PLB binds
all conformations of SERCA, and merely slows the binding of calcium and transition to
the E1 conformation. Evidence for both models stems from assessment of the ability to
bind the E1 conformation (orange boxes), produced by high calcium conditions, with
different methods favoring different models.
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Further studies using a similar approach showed that residue 27 of PLB was in
close proximity to residue 328 of SERCA, and that residues 45-52 of PLB were in close
proximity to residue 89 of SERCA. Crosslinking at these sites was also completely
abolished by increases in Ca2+ concentration, with EC50 values ranging from 100 to 900
nM (Chen, Akin, Stokes, & Jones, 2006; Chen, Stokes, & Jones, 2005).
In a recent study, the Jones group has generated a method to crosslink
endogenous PLB and SERCA2a from isolated human cardiac tissue, generating results
consistent with their previous studies (Akin, Jones, 2012). This is an advancement over
previous studies since measurements are made with endogenously expressed proteins
in the most physiologically relevant membrane environment. Any accessory and/or
anchoring proteins would also be intact within this system. Also, neither protein has
crosslinking sites introduced through a mutation that could alter proper function and
interaction.
These studies show the disruption of PLB-SERCA binding at multiple points of
contact by elevated Ca2+ concentrations. While some residual level of crosslinking (5%
of control) can be observed even at saturating concentrations, the Jones group states
Ca2+ completely abolishes crosslinking. The Jones group then concludes that PLB is able
to compete with Ca2+ for its binding site on SERCA, and that complete dissociation of
PLB and SERCA is required for restoration of SERCA activity.
Their approach and conclusions are supported by additional studies exploring
the effects of PLB phosphorylation on PLB-SERCA crosslinking. Much like elevated Ca2+

25
concentration, phosphorylation of PLB is known to overcome SERCA inhibition by PLB.
Also like elevated Ca2+, they demonstrated that PKA phosphorylation of PLB prevented
crosslinking between PLB and SERCA (Chen, Akin, & Jones, 2007). This further supports
their previous conclusion that relief of PLB inhibition is accomplished through the
unbinding of PLB from SERCA.
The Dissociation Model is also supported by immunoprecipitation studies by the
MacLennan group. They first demonstrated that inhibitory ability of various mutants
(loss and gain of function) correlates with their ability to co-immunoprecipitate with
SERCA (Asahi, Kimura, Kurzydlowski, Tada, & MacLennan, 1999). Subsequently, they
demonstrated that Ca2+ can also disrupt the ability of PLB to co-immunoprecipitate with
SERCA (Asahi, McKenna, Kurzydlowski, Tada, & MacLennan, 2000).

These studies

demonstrate that relief of inhibition correlates to loss of PLB-SERCA interaction, in
support of the Jones group conclusions.
Despite the clear and well characterized results of the crosslinking and
immunoprecipitation assays, the approaches and subsequent conclusions have
limitations. While the crosslinking assay is highly sensitive and specific, the close
proximity of targeted residues on PLB and SERCA are only assessed. Even subtle
changes in the position and/or orientation of PLB in relation to SERCA could prevent the
crosslinking. Small rotations in the transmembrane helices of SERCA could prevent
access of the chemical crosslinkers to the target residues. These factors demonstrate
how crosslinking could be abolished without significant dissociation of the PLB-SERCA
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complex.

Furthermore, even at saturating Ca2+ concentrations, a low level of

crosslinking is observed in many cases. This observation is not in agreement with
complete dissociation.
Despite agreement between crosslinking and immunoprecipitation on the effect
of Ca2+ on the PLB-SERCA interaction, the observations from these approaches differ
under other conditions. A SERCA ligand, thapsigargin, as well as phosphorylation of PLB
have been shown to block the PLB-SERCA crosslinking (Chen et al., 2006, 2005), but
neither affects PLB-SERCA co-immunoprecipitation (Asahi et al., 2000).
The largest complication with immunoprecipitation is that the membrane is
perturbed by detergents prior to the detection of the interaction between PLB and
SERCA. Immunoprecipitation between membrane bound proteins like PLB and SERCA
will be highly susceptible to variations in experimental conditions.

Furthermore,

antibodies targeted to PLB, such as those used to pull down the PLB-SERCA complex in
the co-immunoprecipitation experiments, have themselves been shown to block PLBSERCA crosslinking (Chen et al., 2007) and relieve PLB inhibition of SERCA (Cantilina,
Sagara, Inesi, & Jones, 1993; Y Kimura et al., 1991; Morris, Cheng, Colyer, & Wang, 1991;
Sham, Jones, & Morad, 1991). These factors may explain the inconsistent results
between the two approaches. These factors also argue why immunoprecipitation may
not be an effective strategy to investigate PLB-SERCA binding and therefore may not
lend the crosslinking studies sufficient corroborating support.
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The Dissociation Model is described by the competitive binding of PLB and Ca2+
for SERCA. In competitive inhibition, Ca2+ binding (activity) can always be overcome by
further increases in the concentration of inhibitor. However, this is inconsistent with
studies measuring the dose response of PLB. The maximal inhibition of SERCA, indicated
by decreased apparent Ca2+ affinity, is achieved by a 2.6 fold increase of PLB expression
(Brittsan, Carr, Schmidt, & Kranias, 2000). Further overexpression of PLB does not
enhance the inhibition of SERCA, as would be predicted if PLB competed with Ca2+.
Furthermore, crosslinking is never completely abolished even at saturating
concentrations inconsistent with the Jones group conclusions and the concept of
competitive inhibition.
Subunit Model
In contrast to the Dissociation Model, the Subunit Model has been proposed
suggesting that PLB can remain bound to SERCA throughout its reaction cycle as
depicted in Fig. 6B. The decrease in apparent Ca2+ affinity is achieved by slowing a rate
limiting step of the reaction cycle, likely the on-rate of Ca2+. This is consistent with the
observation that high Ca2+ can overcome inhibition by PLB.
Support for this model first comes from a study showing that a PLB antibody
enhances Ca2+ transport by SERCA in isolated cardiac vesicles (Cantilina et al., 1993).
This antibody produces an increased formation of the autophosphorylated SERCA
intermediate (E1-P) as would be expected with increased activity and turnover of the
pump. However, this antibody was unable to alter the Ca2+ binding in the absence of
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ATP at equilibrium.

This suggests that SERCA inhibition by PLB is not achieved by

lowering the actual affinity of Ca2+ for the pump. The decrease in apparent Ca2+ affinity
in the presence of PLB is then achieved by a decreased turnover of the SERCA pump.
Decreased turnover is explained by a slowed transition from the E2 to E1 conformations
produced by a slower Ca2+ on-rate.
These equilibrium binding experiments were performed in the absence of ATP,
which has been viewed as a flaw. Since ATP is a critical and necessary for SERCA
function, it could then alter the Ca2+ affinity and control how PLB might affect this
equilibrium. The conclusion that PLB decreases the on-rate of Ca2+ has then been
disputed on this assertion (Jones et al., 2002). However, no study has described
equilibrium Ca2+ binding in the presence of ATP in the nearly 20 years since Cantilina et
al was published.

This is likely due to the complexity of this seemingly simple

experiment. The presence both Ca2+ and ATP will induce SERCA cycling and Ca2+
transport, thereby preventing equilibrium from being achieved.
Equilibrium Ca2+ binding experiments have also been performed in using purified
proteins in a reconstituted membrane (Hughes, Starling, Sharma, East, & Lee, 1996).
Consistent with Cantilina et al, the results show no effect of PLB on Ca2+ binding at
equilibrium. However, in contrast to Cantilina et al, this study shows no change in the
rate of the SERCA auto-phosphorylation, and suggests that PLB disrupts the off-rate of
Ca2+.
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The Subunit Model is also supported by a study measuring FRET between PLB
and SERCA (Mueller, Karim, Negrashov, Kutchai, & Thomas, 2004). High levels of
energy transfer were detected between purified, fluorescently-labeled PLB and SERCA in
a reconstituted membrane, even at saturating Ca2+ concentrations.

A small but

significant increase in the distance between the fluorescent probes was detected by the
elevation of Ca2+ concentration. This suggests that relief of inhibition occurs through a
structural rearrangement in the PLB-SERCA complex, rather than from complete
dissociation of PLB from SERCA.
One criticism of this study was the use of purified protein in a reconstituted
membrane. Being in such a non-physiological system could disrupt proper interaction
between PLB and SERCA, thereby producing anomalous results.

The membrane

composition and high relative concentration of protein could produce nonspecific
binding. Also, the fluorescent probes themselves could induce aggregation of PLB and
SERCA. However, this argument neglects that the distance estimations between PLB
and SERCA are consistent with the predicted binding location. Furthermore, activity
assays demonstrate that elevated Ca2+ can overcome PLB inhibition in this system.
Since functional regulation occurs, it suggests that the PLB-SERCA binding detected are
specific and not anomalous. Also, if the fluorescent probes were inducing nonspecific
aggregation, this would reduce the ability of PLB to regulate SERCA, which is not
observed. Labeled and unlabeled PLB inhibit SERCA activity to the same degree.
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Structure-Function Relationship of PLB inhibition
PLB is only expressed in cells expressing SERCA2a and not in cells expressing
SERCA1a (MacLennan & Kranias, 2003; Tada & Toyofuku, 1998).

However, the

interaction between PLB and SERCA1a has been extensively studied despite not being
physiological binding partners. This interaction has been studied due to the wealth of
structural information of SERCA1a and the suspected high degree of structural and
functional similarities between the two isoforms (Asahi et al., 1999; Kühlbrandt, 2004;
Morth et al., 2007). Furthermore, PLB has been shown to inhibit SERCA1a and SERCA2a
to the same extent (Toyofuku, Kurzydlowski, Tada, & MacLennan, 1993). PLB also shows
the ability to crosslink both isoforms in a similar manner (Chen et al., 2006, 2005; Jones
et al., 2002; Toyoshima et al., 2003). The study of the PLB-SERCA1a therefore aids in the
better modeling of the PLB-SERCA interaction. Despite these extensive similarities, our
lab has shown that PLB has a higher affinity for SERCA1a compared to SERCA2a (Hou &
Robia, 2010). While this observation does not discount the other similarities, it is an
important consideration when interpreting the results from SERCA1a.
The hallmark of PLB inhibition of SERCA is a reduced apparent affinity of Ca2+
(increased KCa as in Fig. 5) which is generally thought to occur through transmembrane
interactions of the two proteins (MacLennan & Kranias, 2003).

This concept is

supported by studies showing that a truncated PLB lacking the cytosolic domain was
capable of reducing Ca2+ sensitivity of SERCA to the same degree as full length PLB
(Hughes et al., 1996; Y Kimura, Kurzydlowski, Tada, & MacLennan, 1996). Evidence for
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the role of transmembrane interactions also comes from a homolog of PLB, sarcolipin
(SLN). The transmembrane regions of PLB and SLN have a high degree of similarity, but
SLN lacks a comparable cytosolic domain ( a Odermatt et al., 1997). Despite the lack of
cytosolic domain, SLN displays the ability to reduce the apparent affinity for Ca2+ of
SERCA like PLB (MacLennan, Asahi, & Tupling, 2003; a Odermatt et al., 1998).
While the role of the transmembrane region in the inhibition of SERCA is well
described, the role of the cytosolic domain of PLB is less understood. PLB can inhibit
both SERCA1a and SERCA2a, but is unable to inhibit SERCA3 (Kimura et al., 1996).
However, a truncated PLB lacking the cytosolic domain is able to inhibit SERCA3
indicating a critical role for the cytosolic domain. A region in the nucleotide binding
domain of SERCA3 was identified that prevented regulation by PLB (Toyofuku et al.,
1993; Toyofuku, Kurzydlowski, Tada, & MacLennan, 1994).

Specifically, when the

SERCA3 sequence of Gln-Gly-Glu-Gln-Leu401 was converted to the corresponding
SERCA2a sequence of Lys– Asp–Asp–Lys–Pro401, SERCA3 gained the ability to be
regulated by PLB. However, a specific role for this sequence has not been determined,
but these findings point to at least some regulatory role of the PLB cytosolic domain that
does not directly confer inhibition.
A direct inhibitory function of the cytosolic domain has been suggested and
investigated, though the findings have not been consistent.

Many studies have

examined the potential effect in isolated cardiac vesicles. Early studies suggested that
phosphorylation of the cytosolic domain of PLB could enhance the maximal catalytic
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rate (Vmax) of SERCA in isolated cardiac SR vesicles (Adunyah, Jones, & Dean, 1988).
However, later studies disputed these findings showing that phosphorylation of PLB had
no effect on Vmax in isolated cardiac vesicles ( a Mattiazzi, Hove-Madsen, & Bers, 1994;
M A Movsesian, 1992; Matthew A Movsesian, Colyer, Wang, & Krall, 1990). An isolated
peptide corresponding to the PLB cytosolic domain (residues 1-31) was shown to
decrease the Vmax of SERCA with no impact on Ca2+ affinity (Sasaki, Inui, Kimura, Kuzuya,
& Tada, 1992). These results were supported by studies showing that the removal of
the PLB cytosolic domain through tryptic digestion (Lu & Kirchberger, 1994; Lu, Xu, &
Kirchberger, 1993) caused an increase in the Vmax of SERCA in isolated cardiac vesicles.
Exposure of an antibody targeted to the cytosolic domain of PLB to isolated vesicles was
shown to decrease Vmax in one study (Antipenko, Spielman, Sassaroli, & Kirchberger,
1997) while having no effect on Vmax in another (Cantilina et al., 1993). Variations in
vesicle preparation were shown to impact detection of a Vmax change potentially
explaining the differing results (Antipenko, Spielman, & Kirchberger, 1999).
Rather than using isolated vesicles, many labs studied the role of the cytosolic
domain by expressing PLB an SERCA in heterologous cells or reconstituted them in a
purified membrane. When SERCA was reconstituted into a membrane with and without
PLB, the expected change in KCa was observed with no change in the Vmax parameter
(Reddy et al., 1995; Reddy, Jones, Pace, & Stokes, 1996). These studies also observed no
change in SERCA activity in response to the isolated peptide corresponding to residues
1-31 of PLB. These studies were also supported by an analogous study expressing PLB
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and SERCA in HEK cells also showing no change in the Vmax parameter (A. Odermatt,
Kurzydlowski, & MacLennan, 1996). These studies have been disputed by another group
showing that the isolated PLB cytosolic domain can decrease Vmax in a reconstituted
system and that a truncation of PLB removing the cytosolic domain increases Vmax
(Hughes, East, & Lee, 1994; Hughes et al., 1996; A. P. Starling, Hughes, Sharma, East, &
Lee, 1995). They also demonstrate that experimental conditions used to reconstitute
PLB and SERCA have an effect on the observation of a Vmax change (A. P. Starling et al.,
1995), much like Antipenko et al describes with vesicle preparations (Antipenko et al.,
1999).
While phosphorylation of PLB is known to favor pentamer formation, mass
action equilibrium binding changes may not fully explain the relief of PLB inhibition
through phosphorylation. Phosphorylation of PLB has been shown to prevent chemical
crosslinking to SERCA (Chen et al., 2007), which is in agreement with the idea of mass
action changes. However, our lab has shown using FRET that phosphomimetic mutants
of PLB can interact with SERCA, though with a diminished affinity and altered structure
compared to wild-type PLB (Hou, Kelly, & Robia, 2008). This structure change in the
regulatory complex might also be linked to relief of inhibition. EPR amd NMR studies
have been used to show that phosphorylation of PLB introduces disorder into the alphahelix of the cytosolic domain (Metcalfe, Traaseth, & Veglia, 2005) and that this
phosphorylation does not alter the affinity of the transmembrane domain for SERCA
(Traaseth, Thomas, & Veglia, 2006). To explain the PLB-SERCA inhibitory mechanism as
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well as the effect of phosphorylation on this mechanism, the Veglia group proposes an
allosteric model of PLB interaction (Traaseth et al., 2006; Zamoon, Nitu, Karim, Thomas,
& Veglia, 2005).

They propose that PLB is in equilibrium between two states, an

ordered T state and a disordered R state. In both states, the transmembrane domain of
PLB is capable of interacting with SERCA, but only the T state can inhibit SERCA.
Unphosphorylated PLB favors the order T state and is therefore inhibitory, while
phosphorylated PLB favors the disordered R state and is unable to inhibit.
Predicted PLB Binding Location
A structure of a co-crystal between SERCA1a and PLB monomer has been
determined using cryo-electron microscopy, though not to sufficient resolution to
determine the binding location of PLB (H. S. Young, Jones, & Stokes, 2001). Scanning
alanine mutagenesis of SERCA1a indentified several residues on helix M6 critical for PLB
inhibition suggesting that this helix is a likely point of contact (M Asahi et al., 1999). This
observation was consistent

with later

molecular modeling positioning the

transmembrane domain of PLB in close proximity to helix M6 (Hutter et al., 2002).
Using distance constraints from PLB-SERCA crosslinking studies, subsequent modeling
predicts that the transmembrane domain of PLB is positioned in a groove comprised of
helices M2, M4, and M6 of SERCA (Fig. 7A) (Toyoshima et al., 2003). This study utilized
crosslinking results from both SERCA1 and SERCA2a since the distance constraints were
compatible. The consistency in the crosslinking studies also demonstrates that PLB
likely interacts with SERCA1a and SERCA2a in a similar manner.
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Figure 7: Predicted regulator binding locations. (A) Crosslinking studies predict PLB (red)
to interact with SERCA in a binding pocket described by helices M2, M4, and M6 (blue).
(B) Co-crystalization has provided evidence of that PLM (red) interacts with NKA with a
more exterior helix M9 (green).
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While the positioning of the transmembrane domain of PLB in relation to SERCA
is well supported, less is known about the binding location of the cytosolic domain.
Initial crosslinking studies predicted that Lys3 of PLB interacts with either Lys397 or Lys400
of SERCA (James, Inui, Tada, Chiesi, & Carafoli, 1989). This observation is supported by a
study showing that the sequence Lys– Asp–Asp–Lys–Pro–Val402 in SERCA is critical for
PLB regulation (Toyofuku et al., 1994). These results have been used to model the
position of the cytosolic domain. However, subsequent crosslinking studies have been
unable to provide corroborating evidence calling the initial study into question (Chen,
Stokes, Rice, & Jones, 2003).
Insights into the PLB-SERCA regulatory complex structure may also come from
homologous proteins, Na, K-ATPase (NKA) and phospholemman (PLM). NKA is a P-type
ion pump like SERCA and is thought to function in a similar manner (Kühlbrandt, 2004;
Wuytack et al., 2002). The X-ray crystal structure of NKA shares a high degree of
resemblance to that of SERCA (Morth et al., 2007) further supporting their potential
functional similarities.

PLB and PLM are structurally homologous having a single

transmembrane domain and a cytosolic domain capable of being phosphorylated. Much
like PLB and SERCA, PLM inhibits NKA by reducing ion affinity (Bers & Despa, 2009).
Taken together, these observations suggest a high likelihood that PLB and PLM interact
with their partners in a similar way. Unlike PLB and SERCA, a high resolution crystal
structure has been determined for PLM and NKA (Shinoda, Ogawa, Cornelius, &
Toyoshima, 2009). Rather than showing interaction in the M2/M4/M6 binding groove
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predicted for PLB, PLM interacts with the more exterior helix M9 of NKA (Fig. 7B). Due
to the similarities between the proteins, this suggests the possibility of an alternative
binding site on SERCA for PLB. However, this observation has not been supported
through alternative approaches like crosslinking or mutagenesis, so it could be an
artifact of crystallization. While unlikely due to the high degree of similarity, it is also
possible that PLB and PLM confer inhibition through alternative means and binding
sites.

Potential Interacting Proteins
While PLB and SERCA are a clear functional unit, one must also consider the
possibility that additional proteins may interact with PLB and SERCA in a larger protein
complex. Therefore, additional proteins may alter SERCA function and the ability of PLB
to inhibit in a physiological setting. This has not been a heavily studied area, but there
are several proteins of interest that have been identified. As with many proteins that
can be phosphorylated by PKA, PLB has been found in complex with an A kinase
anchoring protein (AKAP) and has been shown to affect the phosphorylation status of
PLB in vivo (Lygren et al., 2007; Manni, Mauban, Ward, & Bond, 2008). The antiapoptotic HS-1 associated protein X-1 (HAX-1) has been shown to interact with SERCA
and regulate its expression (Vafiadaki et al., 2009). HAX-1 overexpression has been
shown to reduce contractility of cardiac myocytes, and this effect was abolished in the
PLB knockout mouse (Zhao et al., 2009). HAX-1 was identified as a binding partner of
PLB using the yeast two-hybrid method (Vafiadaki et al., 2007) and was shown to
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destabilize PLB pentamer formation (Vafiadaki et al., 2009). Histidine rich Ca2+ binding
protein (HRC) is an SR Ca2+ buffering protein that has been shown to have a regulatory
role in Ca2+ release via triadin and the ryanadine receptor. Additionally, HRC has been
shown to interact with SERCA and alter Ca2+ sequestration (D. a Arvanitis et al., 2007;
Pritchard & Kranias, 2009). This dual role for HRC suggests a potential crosstalk role
between Ca2+ uptake and release.

Disease and Therapy
Physiological Principles of Disease
SERCA activity maintains SR Ca2+ load which is a primary determinant of Ca2+
release and contractility (Bers, 2008). Decreases in SERCA activity would then seemingly
be associated with reduced contractility, a general characteristic of heart failure. In
many observed cases, decreased SERCA activity has indeed been related with heart
failure (Hasenfuss, 1998; Phillips et al., 1998; Wickenden et al., 1998). In most but not
all cases, decreased SR Ca2+ content has been observed with heart failure. In many
instances, this decreased SR Ca2+ content has been connected to depressed SERCA
function. However, increased activity of the Na, Ca-exchanger has also been implicated
in reduced SR content when no change in SERCA function was observed (Bers, 2008;
Hobai & Rourke, 2000; Houser, Piacentino, Mattiello, Weisser, & Gaughan, 2000;
Pogwizd, 2000).

Depressed SERCA function associated with heart failure can be

attributed to decreased expression of SERCA2a or enhanced inhibition from SERCA.
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There are no mutations in SERCA2a known to cause a predisposition of heart
failure (Kranias & Bers, 2007). In the only screen of SERCA2a mutations in heart failure
patients, only 4 point mutations were found, all of which were conserved mutations
resulting in no change in the amino acid sequence (Schmidt et al., 2003). This suggests
that genetic polymorphisms are not likely to account for differences in SERCA activity in
heart failure patients. Darier’s disease is characterized as a haploinsufficiency of the
SERCA2 gene resulting in a skin disorder (Brini & Carafoli, 2009; Dally, Corvazier,
Bredoux, Bobe, & Enouf, 2010). Interestingly however, adult Darier patients are not
predisposed to heart failure suggesting a robust compensatory mechanism for cardiac
SERCA expression or sufficient expression from one allele. It has been speculated that
the lack of genetic variation within SERCA2a suggests that even minor changes to
SERCA2a activity cannot be tolerated and are incompatible with life (Kranias & Bers,
2007).
While there are no known SERCA mutations associated with heart failure, there
have been 3 important mutations identified within PLB associated with dilated
cardiomyopathy.

A substitution of Arg9 for Cys (R9C) has been shown to impair

phosphorylation of PLB, thereby enhancing inhibition of SERCA (Brini & Carafoli, 2009;
Ha et al., 2011; Schmitt et al., 2003). A premature stop codon at Leu39 (L39stop) has
been shown prevent proper insertion of PLB into the SR membrane thereby preventing
its ability to regulate SERCA (Kranias & Bers, 2007). The deletion of Arg14 (R14del) is
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thought to enhance the interaction with SERCA, thereby increasing the inhibition of
SERCA (Haghighi et al., 2006).
Therapeutic Targets
Since decreased contractility is a component of heart failure, enhancing SR load
through increased SERCA activity is a logical therapeutic path. This concept is supported
by studies showing that increasing SERCA2a expression levels through gene transfer in a
failing mouse heart model has be ability to restore contractility (Del Monte, Hajjar,
Harding, & Inesi, 2001). In fact this approach is currently in human clinical trials.
Decreasing the ability of PLB to inhibit SERCA is also a potential target for therapy. A
phosphomimetic PLB mutant (S16E) which has a decreased ability to inhibit SERCA has
been shown to be capable of relieving SERCA inhibition in heart failure (Hoshijima et al.,
2002). Also ablation of PLB through antisense DNA transfer has been effective in
restoring contractility in a rat failing heart model (Tsuji et al., 2009). While PLB ablation
or replacement with non-inhibitory mutants might provide an effective means of
restoring contractility, deleterious effects might arise from an inability of SERCA function
to respond to β-adrenergic stimulation.

Therefore, development of designer PLB

mutants that have a reduced ability to inhibit SERCA while retaining the ability to
respond to phosphorylation would be a significant improvement of this approach.

CHAPTER III

MATERIALS AND METHODS

Overview of Fluorescence Resonance Energy Transfer
Fluorescence Resonance Energy Transfer (FRET) is a highly effective means of
detecting protein-protein interactions and is the predominant methodology I have
utilized for this work. A thorough description of FRET can be found in Principles of
Fluorescence Spectroscopy 3rd Edition (Lakowicz, 2006), but will a brief description of
FRET will be provided here.
FRET utilizes the biophysical property of appropriately paired fluorescent
molecules (donor and acceptor) that causes the transfer of light energy when in close
proximity (<100 Å). This study uses Cerulean (CFP derivative) and YFP as the donor and
acceptor fluorophores, respectively. When Cerulean is excited, the energy can be
emitted from that fluorophore as a photon of blue light or transferred to YFP (exciting
YFP) causing the emission of a photon of yellow light. The percent of the donor
excitation energy that is transferred to the acceptor is known as a FRET Efficiency (E). E
is commonly determined through quantification of the donor and acceptor fluorescence
intensities.

This work uses the acceptor-photobleaching and E-FRET methods to

measure FRET and both are discussed in detail below. When these fluorophores are
attached to proteins that interact (e.g., SERCA and PLB), the fluorophores can be (but
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not always) in close enough proximity to undergo energy transfer.

Observed energy

transfer therefore provides an indicator of interaction of the target molecules. E is
highly sensitive to and can measure the distance between the fluorophores (inversely
related to the distance to the power of 6). Therefore E is more than just an indicator of
interaction since it provides some information about the orientation of the interacting
proteins by producing a distance constraint.

Acceptor Photobleaching
Acceptor photobleaching experiments were performed with an inverted
microscope equipped with a 60X 1.49 NA objective, and a back-thinned CCD camera
(iXon 887, Andor Technology, Belfast, Northern Ireland). The detector was cooled to 100 °C, using a recirculating liquid coolant system (Koolance, Inc., Auburn, WA). Image
acquisition and acceptor photobleaching was automated with custom software macros
in MetaMorph (Molecular Devices Corp, Downingtown, PA) that controlled motorized
excitation/emission filter wheels (Sutter Instrument Co., Novato, CA) with filters for
CFP/YFP/mCherry (Semrock, Rochester NY). The progressive photobleaching protocol
was as follows: 100 ms acquisition of CFP image, 40 ms acquisition of YFP image,
followed by 10 s exposure to YFP-selective photobleaching (504/12 nm excitation. FRET
efficiency was calculated from the fluorescence intensity of the CFP donor before and
after acceptor-selective photobleaching, according to the relationship:

E = 1 -

(FPrebleach/FPostbleach). Representative pre and post bleach images are shown in Fig. 8A
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Figure 8: Acceptor Photobleaching FRET. (A) CFP and YFP images pre and post YFP
photobleaching. After photobleaching, the YFP fluorescence is abolished while CFP
fluorescence has been enhanced. (B) Average normalized fluorescence intensity of CFP
(blue) and YFP (green) during the course of YFP photobleaching. CFP intensity increases
with decreasing YFP intensity.
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displaying enhanced CFP fluorescence corresponding to abolished YFP fluorescence. Fig.
8B shows the time course of average fluorescent intensity of CFP increasing as average
fluorescent intensity of YFP decreases.

E-FRET
I have also utilized E-FRET or “3-cube” FRET (Hou & Robia, 2010; Zal &
Gascoigne, 2004) rather than acceptor-photobleaching to improve on the speed to data
collection.

Measurements are consistent with the well established acceptor

photobleaching method that our lab has previously used (Hou & Robia, 2010; Hou et al.,
2008; Kelly et al., 2008). For these measurements, we used a similar microscope setup
described above for acceptor photobleaching. For each sample, automated acquisition
of a field of 48 images was performed using a motorized stage (Prior, Rockland, MA)
controlled by MetaMorph software. Focus was maintained by an optical feedback
system (Perfect Focus System, Nikon). Images were obtained with a 40X 0.75 N.A.
objective with 100 ms exposure for each channel: Cer, YFP, and “FRET” (Cer
excitation/YFP emission). Fluorescence intensity was automatically quantified with a
multi-wavelength cell scoring application in MetaMorph. Cell selection criteria included
having a diameter of 35-75 pixels and having an average intensity of 100 counts above
background. The data were transferred automatically to a spreadsheet for analysis. EFRET is a ratiometric FRET estimation calculated from
E=

IDA − a(I AA ) − d (IDD )
IDA −a(IAA )+(G −d )(IDD )
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where IAA is the intensity of fluorescence emission detected in the donor channel
(472/30 nm) with excitation of 427/10 nm; IAA is acceptor channel (542/27 nm) emission
with excitation of 504/12 nm; IDA is the “FRET” channel, with 542/27 nm emission and
excitation of 427/10 nm; a and d are cross-talk coefficients determined from acceptoronly or donor-only samples, respectively.

We obtained values for d of 0.82 for

mCerulean, and a value for a of 0.082 for YFP. G is the ratio of the sensitized emission
to the corresponding amount of donor recovery, which was 3.2 for this setup.

Binding Curves and Fitting Analysis
In addition the distance between the fluorescent probes, the percentage of
targets engaged in energy transfer determines the FRET efficiency of an individual cell.
Expression and affinity of the targets will dictate this percentage, causing FRET efficiency
to vary within a population of cells with heterogeneous protein expression. When the
FRET efficiency of individual cells is plotted against PLB protein concentration estimated
by the YFP-PLB fluorescence intensity, FRET efficiency increases with protein expression
up to a maximal level and can be well described by a hyperbolic function, y =
(FRETmax)x/(KD2 + x) An example scatter plot is shown in Fig. 9A along with its
corresponding hyperbolic fit in black. 300-800 cells are typically used to develop a single
binding curve. FRETmax describes the intrinsic FRET between SERCA and PLB where FRET
is limited only by the distance between the probes, providing structural information (Fig.
9A, blue). KD is the protein concentration at half maximal FRET which represents the
dissociation constant of the regulatory complex providing an affinity index (Fig. 9A, red).

A
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Figure 9: Quantitative analysis of protein concentration dependence of FRET. FRET
efficiency varies within a population of cells, and can be related to protein concentration
with a hyperbolic function. A representative scatter plot of individual cell values is
shown along with corresponding fitting curve (A, B, black). (A) The FRET efficiency that
the fitted curve is approaching is known as FRETmax (blue dashed line), the intrinsic FRET
value that limited only by the distance between the fluorescent probes. The protein
concentration at half maximal FRET efficiency is the KD value (red dashed lines). (B) The
blue line corresponds to a sample with a decreased FRETmax, or increased distance. The
red line corresponds to a sample with a reduced affinity.
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The absolute values of FRET obtained through our methodology include some
level of uncertainty.

Due to their unstructured linkage with PLB and SERCA, the

fluorescent proteins likely retain a high degree of flexibility with respect to the target
proteins. The fluorescent proteins are also relatively large. In combination, these two
factors limit the ability of our method to make precise structural conclusions. Presently,
we are unable to determine specific concentrations from these fluorescence
measurements. Therefore our concentration parameter is presented in arbitrary units
(AU) rather than molar units. Therefore, changes or shifts in these FRETmax and KD
parameters provide more significant information than do their absolute values. The red
and blue curves in Fig. 9B represent simulations of changes in affinity and structure,
respectively. The right-shifted curve in red represents where data corresponding to
reduced affinity should fall. The down-shifted curve in blue represents a distance
increase corresponding to a structure change.
Non-specific FRET, or energy transfer between close but non-interacting targets,
is a concern with FRET measurement, especially if the targets are constrained to the
membrane. While we presently have no true negative control for PLB-SERCA FRET, we
have estimated non-specific FRET through a competition assay. Addition of increasing
amounts of unlabeled protein decreases FRET efficiency in our system to 4% (Hou &
Robia, 2010). Therefore, even at the highest expression levels, only 4% of the measured
FRET efficiency is accounted for by non-specific FRET.
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Confocal Microscopy
Confocal Images
To verify proper expression of YFP-PLB and Cer-SERCA2a, high resolution
confocal images were taken of infected myocytes. To visualize sarcolemma and ttubules, cells were also stained with FM 4-64 (Invitrogen) according to manufactures
instructions.

Briefly, dye at a stock concentration of 1 mM was diluted to a

concentration of 1 µM in PC-1 medium was used to bathe cells for approximately 10
min, after which cells were washed in additional PC-1 to remove excess dye. Images
were obtained using an inverted Leica TCS SP5 confocal microscope with a 63x water
immersion objective and an 8000 Hz resonant scanner. Cer, YFP, and FM 4-64 were
sequentially excited using an argon laser with wavelengths of 458, 514, and 543 nm,
respectively.
Confocal Scanning
Confocal scanning microscopy was used obtain simultaneous and high temporal
resolution of FRET and Ca2+ concentration measurements in paced adult ventricular
myocytes. As an index of FRET, the ratio of YFP/Cer fluorescence intensities was
obtained with 458 excitation and detection of YFP (525-560 nm) and Cer (470-515 nm)
using the Leica system described above. Cells were loaded with X-Rhod-1 AM as an
indicator of Ca2+ concentration which was detected with 543 nm HeNe laser excitation
and an emission range of 570-650 nm. Myocytes were perfused with PC-1 medium
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during data collection. Experiments were conducted in x-t mode to study individual Ca2+
transients and x-y-t mode to study alternating periods of pacing and rest.

Tissue Culture
Heterologous Cell Culture and Transient Transfection
AAV-293 cells were cultured in complete DMEM growth medium (HyClone,
Waltham, MA) with 10% fetal bovine serum (heat inactivated) (HyClone, Waltham, MA),
2mM L-glutamine (CellGro, Manassas, VA). Cells were split every few days once a
confluency of 90-95% had been reached. Cells at approximately 70-80% confluency
were transfected according to manufacturer’s instructions, using MBS Mammalian
Transfection Kit (Stratagene, La Jolla, CA). 6% modified bovine serum was used instead
of the 10% suggested by the manufacturer during the three hour incubation of cells with
the CaPO4-DNA precipitate. Two days after transfection, cells were trypsinized and
plated onto poly-D-lysine coated glass bottom dishes and incubated at 37 C for
approximately 2 hours to permit cell attachment before data acquisition.
For Tg exposure, cells were washed 2 times with PBS, and then bathed in PBS
containing the appropriate concentration of Tg, 10 pM – 100 uM. For Ca2+ experiments,
cells were permeabilized with 10 µg/ml saponin for 1 min. and then washed in bath
solution of composition 100 mM KCl, 5 mM NaCl, 2 mM MgCl2, 20 mM imidazole, 5 mM
EGTA, and 2 mM ATP (pH 7.0), with varying free Ca2+. Ca2+ concentration was calculated
with Maxchelator (Schoenmakers, Visser, Flik, & Theuvenet, 1992) and validated with a
Ca2+-sensitive electrode (Thermo Scientific, Waltham, MA).
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Myocyte Culture and Adenoviral Infection
The Ca2+ phosphate transfection system used to express our fusion proteins in
AAV-293 is insufficient for expression in adult myocytes. We therefore developed
adenoviral vectors of canine Cer-SERCA2a and canine YFP-PLB using the AdEasy system
(Stratagene, La Jolla, CA). Cardiac ventricular myocytes were isolated from adult New
Zealand White rabbits by a collaborating lab as previously described (Domeier, Blatter,
& Zima, 2009). All protocols were approved by the Loyola University Institutional
Animal Care and Use Committee. Myocytes were transferred to culture tubes and
washed with PC-1 medium (Lonza, Basel, Switzerland) containing penicillin and
streptomycin (Invitrogen).
Myocytes were cultured in dishes containing laminin coated glass coverslips and
adenoviruses were added at multiplicity of infection of 100. Sufficient expression of our
constructs required approximately 48 hours of culture, however viability of the
myocytes declines rapidly. To improve viability, myocytes were paced in culture using a
C-Pace EP pacer (IonOptix, Milton, MA) set to 10 volts with a frequency of 10 Hz and 5
ms pulse duration.
Calcium Indicator
Experiments required both AAV-293 and adult myocytes to be loaded with a redshifted fluorescent Ca2+ indicator, X-Rhod-1 AM (Invitrogen). The dye was resuspended
in Pluronic® F-127 *20% solution in DMSO (Invitrogen) to a concentration of 1 mM, and
sonicated briefly to aid in solubilization. This stock solution was diluted to 1 µM in
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either PBS or PC-1, which was used to bathe the cells for 2 min. Cells were then washed
gently 3x in either PBS or PC-1 and equilibrated for 20 min prior to imaging.

CHAPTER IV

LIVE CELL CALCIUM UPTAKE ASSAY

Rationale for Development of Assay

Much of the work done for this dissertation and other work in our lab utilizes
fluorescent protein fusions. These fusion proteins enable the detection of proteinprotein interactions with FRET in live cells, in real-time.

While this methodology

provides significant advantages, it is not without drawbacks. How the attachment of
relatively large fluorescent proteins will affect our target proteins is a valid concern.
Therefore, assessing the functionality of our fusion proteins is a necessary step in
validating our overall approach.
Traditional SERCA activity assays such as ATP consumption and Ca2+ uptake are
needed to quantify the activity of SERCA and the ability of PLB to inhibit this activity.
These assays are necessary to directly compare the activities of wild type SERCA and PLB
to our fusion proteins. However, these assays can be difficult and time consuming.
Having an alternative method to rapid screen for function is therefore highly beneficial
for our lab. To complement more direct quantification of our fusion protein activity that
our lab has undertaken, we developed an indirect live cell Ca2+ uptake assay, the
particulars of which are discussed below.
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Protocol
AAV-293 cells are transfected with various constructs as discussed previously. 24
hours post-transfection, cells are plated on poly-D-lysine coated glass slides, and
allowed to attach for 2 hours also discussed previously. Ca2+ indicator loading is
described in the Materials and Methods section. Briefly, cells are washed 2 times with
PBS containing 2 mM Ca2+ and loaded with a red-shifted Ca2+ indicator, X-Rhod-1, AM.
Cells are washed an additional 3 times to remove excess dye, and cells are bathed in PBS
containing 2 mM Ca2+ for 20 min.
First, a 100 ms CFP or YFP is taken to assess transfection status of cells in a given
field of view. Then a mCherry or red channel image is then taken every 5 secs for
approximately 8 min (100 images). At the 1 min time point, a sufficient baseline X-Rhod
signal has been obtained, at which 100 µM ATP is added to the cells. 4 min later, 10 mM
thapsigargin is added, and data collection continues for approximately 3 more minutes.
The mean X-Rhod and std. error of 30-60 cells is plotted against time.
With typical transfection efficiency around 50-60%, there generally is a
heterogeneous population of transfected and untransfected cells in any field of view.
This is depicted in Fig. 10A showing CFP, YFP, and red channel images along with the
corresponding overlay. This field contains both transfected (T) and untransfected (UT)
cells. This allows simultaneous data collection from expressing and non-expressing cells,
thereby providing an internal control within the experiment.
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Principle of Assay and Results
Activation of cell surface purinergic receptors through ATP stimulation induces
an IP3 mediated Ca2+ release in many cell types, including AAV-293 (Ralevic & Burnstock,
1998). Endogenous SERCA Ca2+ uptake is initially overwhelmed by this release event,
causing Ca2+ to accumulate in the cytosol. Desensitization of purinergic receptors and
IP3 degradation halts Ca2+ release, preventing further accumulation, and allowing the
endogenous SERCA to lower cytosolic Ca2+ to basal concentrations. If cells are loaded
with a fluorescent Ca2+ dye, a spike in fluorescence intensity following ATP stimulation
will be observed (Fig. 10B, black). In cells overexpressing our Cer-SERCA, we observed
that this spike was nearly abolished (Fig. 10B, red). We believe that enhanced SERCA
activity due to overexpression of our fusion protein is able to keep pace with the Ca2+
release, thereby preventing Ca2+ accumulation.
Because we do not directly measure Ca2+ uptake activity, abolishing Ca2+
accumulation alone is not sufficient to demonstrate SERCA function. Overexpression of
our fusion proteins (Cer-SERCA, YFP-PLB) could deleteriously affect the cell, perhaps
causing a depletion of the ER Ca2+ stores that would prevent a Ca2+ release and
accumulation. There is a constant leak of Ca2+ from the ER, but basal SERCA Ca2+ uptake
maintains low cytosolic Ca2+ concentrations. Blocking SERCA activity will then cause
accumulation of cytosolic Ca2+.

By applying the SERCA inhibitor thapsigargin (Tg)

following ATP stimulation, we are also able to assess ER Ca2+ content of these cells.

55

A

B

Figure 10: Ca2+ uptake in live cells. (A) Wide-field fluorescence images of AAV-293 cells
transfected with Cer-SERCA and YFP-PLB, loaded with Ca2+ indicator X-rhod-1. This field
contains examples of transfected (T) and untransfected (UT) cells. (B) Ca2+ transients
were observed after the addition of extracellular ATP in untransfected cells (black), but
not in cells expressing Cer-SERCA (red), suggesting Ca2+ uptake activity of Cer-SERCA.
Ca2+ transients were partially restored in cells expressing both Cer-SERCA and YFP-PLB
(blue). When compared with untransfected controls, Tg-releasable ER Ca2+ content was
increased by Cer-SERCA. Cells expressing YFP-PLB (green) had reduced Ca2+ transients
and reduced Ca2+ load, suggesting that exogenous PLB inhibited endogenous SERCA.
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In both untransfected (Fig. 10B, black) and cells expressing exogenous SERCA
(Fig. 10B, red), we observed this Tg-mediated Ca2+ accumulation, demonstrating that
expression of our fusion protein does not deplete Ca2+ stores.

In fact, cells

overexpressing Cer-SERCA show a greater Tg-mediated Ca2+ accumulation compared to
untransfected cells, suggesting a greater ER Ca2+ content.

This provides further

evidence of enhanced Ca2+ uptake upon overexpression of our SERCA fusion protein.
Co-expression of Cer-SERCA with YFP-PLB partially restores the ATP-mediated
Ca2+ accumulation to control levels suggesting that YFP-PLB can functionally inhibit CerSERCA (Fig. 10B, blue). Also, this further demonstrates the activity of Cer-SERCA, since
its known inhibitor can diminish its observed effect. Expression of YFP-PLB alone (Fig.
10B, green) showed smaller ATP and Tg-mediated Ca2+ accumulation compared to
untransfected cells, indicating YFP-PLB can regulate endogenous SERCA.

Summary
This assay provides a rapid and clear qualitative assessment of our fusion protein
activity. We observed that Cer-SERCA1a is active, which can be functionally regulated
by YFP-PLB. We also observed that Cer-SERCA2a is also active and can be functionally
regulated by YFP-PLB (not shown). While not used in this work, we have also observed
that a SERCA tagged with two fluorescent proteins (one of which is inserted in the
middle of SERCA) is also active and can be regulated by YFP-PLB (not shown). This
demonstrates that robustness of our system, wherein a complex containing 3
fluorescent proteins can remain functional.

CHAPTER V

Rationale

STEADY-STATE DETECTION OF PLB-SERCA BINDING

As discussed in the Literature Review, multiple models of PLB regulation have
been proposed, but no clear consensus has been achieved despite extensive research on
this interaction. Chemical crosslinking, immunoprecipitation, and FRET studies have
been used to investigate the steady-state PLB-SERCA interaction under various
conditions that favor particular conformations of SERCA. In addition to their strengths,
previous methods have significant limitations. This necessitates additional points of
view from new and alternative approaches. We have used FRET in intact cells to
quantitatively study the PLB-SERCA interaction, a method that has its own strengths and
weaknesses. By using this complementary method, we have sought to tease out some
nuances of the PLB-SERCA interaction and integrate the present data in the field into a
cohesive model.

Mean FRET
Thapsigargin (Tg) is a cell permeable SERCA inhibitor commonly used to block the
Ca2+ uptake of intact cells (Michelangeli & East, 2011). Tg has also been shown to
completely block chemical crosslinking between PLB and SERCA in isolate vesicles (Chen
et al., 2006, 2005; Jones et al., 2002). We therefore initially hypothesized that Tg would
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completely displace PLB from SERCA, and therefore completely abolish PLB-SERCA FRET
in intact AAV-293 cells.

To test this hypothesis we exposed the cells transiently

expressing YFP-PLB and CFP-SERCA1a to either 1 µM Tg or vehicle control in PBS for 10
min. Using the acceptor photo-bleaching method, we then measured the average FRET
efficiency.

We observed that the Tg decreased average FRET efficiency from 13.4

± 1.7% to 5.2 ± 1.1% (Fig. 11A). FRET between PLB and SERCA was decreased, but not

abolished.
In a parallel experiment, we examined the effect of Ca2+ on the average PLBSERCA FRET. As with Tg, we hypothesized that Ca2+ would completely displace PLB from
SERCA based upon chemical crosslinking studies, and therefore completely block PLBSERCA FRET in AAV-293 cells. Cells expressing YFP-PLB and CFP-SERCA1a were bathed in
10 µM ionomycin, a Ca2+ ionophore, for 10 min in PBS with or without 1.8 mM Ca2+.
FRET was then measured in these cells as before. FRET was not significantly decreased
by the presence of high Ca2+ (21.4 ± 2.2% at low Ca2+ and 18.8 ± 2.3% at high Ca2+) (Fig.
11C).
Antibodies targeting PLB have been previously shown to block the ability of PLB
to inhibit SERCA (Cantilina et al., 1993) as well as block PLB-SERCA crosslinking (Chen et
al., 2007). In an additional experiment, we examined the effect of rabbit anti-PLB
(2D12) on PLB-SERCA FRET in AAV-293 cells. Cells expressing YFP-PLB and CFP-SERCA1a
were permeabilized using 20 mg/ml saponin and then bathed in PBS with or without
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Figure 11: Mean PLB-SERCA FRET. The mean PLB-SERCA FRET is decreased by (A) Tg and
(B) PLB antibody (2D12), but not by (C) elevated calcium concentration.
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2D12 antibody.

FRET was then measured in these cells using the acceptor-

photobleaching method. Average FRET was reduced by PLB antibody to 3.9 ± 1.2% from
a control of 9.7 ± 1.1% (Fig. 11B). FRET again was not completely abolished as was
initially hypothesized.
These average FRET results were inconsistent with the published crosslinking
studies which predicted we would observe a complete blockage of FRET with Ca2+, Tg, or
PLB antibody (Chen et al., 2007, 2006, 2005). We observed no significant reduction in
FRET with high Ca2+ concentrations, and only partially reduced FRET in the presence of
Tg and PLB antibody. The lack of the predicted effects could be due to several factors.
Our experimental conditions could have insufficiently saturated our system (incomplete
binding of Ca2+ and Tg to SERCA or 2D12 to PLB) thereby preventing the full dissociation
of PLB from SERCA.

However, our initial hypothesis that PLB would completely

dissociated PLB from SERCA may have also been incorrect.

Protein Dependence of FRET
Using average FRET efficiency from a population of cells as an indicator of
protein-protein interaction is simple and straight forward, but is also very limiting. We
can detect binding and changes in binding, but cannot fully describe these changes. A
decrease in average FRET efficiency could be caused by unbinding or dissociation of a
portion of the proteins undergoing FRET indicating a decrease in affinity. Also, there
could be an increase in the distance between our probes attached to our target proteins
indicating a structure change. We decided further experiments should be analyzed
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using a standard lab protocol showing the dependence of FRET efficiency of a cell on its
protein expression level. This approach has been shown to distinguish between changes
in affinity (KD2) and structure (FRETmax) of the PLB-SERCA regulatory complex (Ha et al.,
2011; Hou & Robia, 2010; Hou et al., 2008; Kelly et al., 2008) as well as the Na, KATPase-phospholemman interaction (Song, Pallikkuth, Bossuyt, Bers, & Robia, 2011).
We are able to observe a clear trend when we plot FRET efficiency of many cells
against their protein concentration, estimated by YFP fluorescence intensity (Fig. 9). In
control cells, FRET increases with protein concentration up to a maximal level and is
described by a hyberbolic function of the form y = (FRETmax)x/(KD2 + x). FRETmax and KD2
values are consistent with previously published work from this lab. Addition of 10 uM
Tg, as described above, causes a rightward shift of the fitted curve (Fig. 12A). KD2 is
increased from 7.0 to 11.9 AU.

We observed no change in the FRETmax parameter.

These two observations suggest that the decrease in average FRET was due to a
decrease in the amount of PLB interacting with SERCA and not an increase in the
distance between the two proteins. While there is reduced binding, there is not a
complete abolishment in binding that we initially hypothesized based on the crosslinking
experiments.
Using this same approach, we further analyzed the Ca2+ effect on PLB-SERCA
binding. Unlike the mean FRET experiment, we utilized PBS containing 1 mM EGTA,
along with 10 µM ionomycin, to further lower Ca2+ concentration. This condition
produced a typical curve approaching a FRETmax of 30.6%. Addition of 2 mM Ca2+ caused
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Figure 12: Protein dependence on FRET, acceptor photobleaching. Both (A) Tg and (B)
elevated calcium cause a rightward shift in the dependence curves, describing a reduced
PLB-SERCA binding affinity.
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a slight rightward shift of the data (Fig. 12B). The control and high Ca2+ datasets
overlap, but are clearly resolvable with an increase of KD2 from 4.5 to 6.0 AU. As with
Tg, the Ca2+ effect on PLB-SERCA binding can be described as a decreased affinity,
partially reducing binding, but not completely abolishing it.
This is unlike the mean FRET result shown previously where no significant Ca2+
effect was observed. Several factors could explain this discrepancy. Use of EGTA could
have partially lowered the control KD2 value thereby producing a change that was not
present in the mean FRET experiment. Also, with the high degree of overlap in the
datasets and a relatively small change in KD2, about a 30% increase, the change may
have been too subtle to observe with the mean FRET approach. This extra dimension
provides an advantage of this binding curve FRET analysis of discerning very subtle
changes.

E-FRET rationale
Although we observed clear results from the acceptor photobleaching approach,
we opted for the E-FRET method to improve the rate of data collection. A two condition
plot such as Fig. 12 would require a full day of data collection, whereas a comparable EFRET plot would take only a few minutes. Therefore it is much easier to compare data
from many different conditions.

With acceptor photobleaching, the time of Tg/ Ca2+

exposure would vary between 30-120 minutes. Due to the shorter time frame of data
collection, Tg or Ca2+ exposure could be more directly controlled, thereby reducing
variability within samples. Additionally, a typical E-FRET plot would have a much larger
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sample size as an added benefit. Fewer coverslips and transfected cells are needed also
improving cost effectiveness of the assay as well.
E-FRET requires calculations with more variables and assumptions, thereby
producing more uncertainty in the absolute FRET efficiencies measured. However, we
observed consistent results with acceptor photobleaching and E-FRET for both the Tg
and Ca2+ effects. The FRETmax parameters were similar between the two approaches.
Because of the different microscope setups used, the KD2 values of the fitted curves,
measured in AU, are not the same between the approaches, but the magnitude of the
KD2 shifts are similar. Because my conclusions are based more on the relative changes
of these curves rather than the specific values, E-FRET was the most effective option for
further experimentation.

Calcium Dose Effect
Rather than using ionomycin, we opted to saponin-permeabilize our cells to
introduce internal solutions with EGTA buffered Ca2+ to more directly control Ca2+
concentration. Cells expressing Cer-SERCA1a and YFP-PLB were permeabilized with 10
µg/ml saponin for 1 min. and then washed in bath solution of composition 100 mM KCl,
5 mM NaCl, 2 mM MgCl2, 20 mM imidazole, 5 mM EGTA, and 2 mM ATP (pH 7.0), with
varying free Ca2+. Free Ca2+ concentration was calculated with Maxchelator.
After 2-3 min in bath solution, the automatic E-FRET acquisition protocol was
performed for each Ca2+ concentration. The fluorescence intensities of cells were
quantified using the Metamorph multiwavelength application, from which FRET
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efficiencies were generated as previously described. Five independent experiments
were performed.
Initially, all datasets were fit by a hyperbolic function of the form y =
(FRETmax)x/(KD2 + x), with all parameters independently fit. Because mean FRETmax was
not significantly different for low and high concentrations of Ca2+, we concluded that
FRETmax did not change in response to changes in Ca2+. Therefore, this parameter was
shared in a subsequent global analysis, yielding a single FRETmax fit with independent KD2
values for each condition.
A typical plot of is shown in Fig. 13A for low (100 pM) and high (1 mM) Ca2+
concentrations with their corresponding fitted curves. The data points are pooled for
visualization, showing average data with error bars corresponding to standard error. A
similar Ca2+ effect was observed with cell permeabilization compared to ionomycin
treatment used previously producing an approximately 40% increase in KD2 value. The
KD2 values generated from all data sets were then plotted against Ca2+ concentration.
Fig. 13B shows the dependence of KD2 on increasing Ca2+ concentration. A modified Hill
function shows a 41% increase in KD2 with Ca2+, with an EC50 of 410 nM and a Hill
coefficient of 1.1.
Calcium Electrode

Since the Maxchelator predicted free Ca2+ concentrations are just theoretical
estimations, they require further validation. Fig. 14A depicts the dose response of Ca2+
using solutions containing 1 mM EGTA, corresponding to the predicted Maxchelator
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Figure 13: Calcium effect on PLB-SERCA FRET, E-FRET. (A) As with acceptor
photobleaching, elevated calcium (red) causes a right-shifted curve compared to control
(black) corresponding to a decreased PLB-SERCA affinity with no change in the FRETmax
parameter (B) The calculated KD2 values from the example fitted curves in A are shown
plotted against calcium concentration. KD2 appears to transition between two affinity
states upon elevation of calcium.
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Figure 14: Calibration of calcium buffered solutions. (A) The initial calcium response
curve with an EGTA of 1 mM with the calcium concentration values measured estimated
by MaxChelator. (B) The calcium calibration curve of our prepared solutions with 1 mM
EGTA (red) compared to standard solutions (black). While in agreement at high calcium
concentrations, our solutions deviated from the known standard solutions at lower
concentrations. (C) The dose curve in A with calcium concentration adjusted using the
voltage curve in B showing that the low calcium solutions were all clustered around the
same concentration. The red curve shows the original fitted curve in A, and the blue
and green curves show other potential curves that could also fit the data set. An
estimate of the high affinity (low KD) state was therefore unable to verified using only 1
mM EGTA. (D) The calcium calibration curve of our prepared solutions with 5 mM EGTA
(red) compared to standard solutions (black) showing agreement of the full range of
calcium concentrations.
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values. Using a Ca2+ sensitive electrode (Thermo Scientific), we compared the free Ca2+
concentration of our solutions, to a set of standard Ca2+ solutions (World Precision
Instruments). As shown in Fig. 14B, we observed good agreement with the standards at
concentrations above 100 nM, but deviation from the standards at lower
concentrations.
Our initial Ca2+ dependence plot is shown in Fig. 14C after correction with the
standard concentration curve. With the low Ca2+ data points clustered around 100nM,
we could not conclude that we were accurately quantifying the lowest possible KD2
value. The blue and green curves represent simulations that could also fit the data,
showing large differences in the potential low KD value.

By increasing EGTA

concentration from 1 mM to 5 mM, our prepared solution were in good agreement with
the standards over the full range of concentrations (Fig. 14D). The experiments were
then independently repeated 5 times with the newly determined solutions. With the
increased EGTA concentration, a slightly larger increase in the KD2 change was observed,
but the overall trend remained the same. While it did not alter our final conclusions, we
further validated our methodology.

Thapsigargin Dose Effect
Using the same high-throughput E-FRET described for Ca2+, we quantified the Tg
effect over a range of Ca2+ concentrations, 10 pM to 100 uM, in AAV-293 cells
expressing YFP-PLB and Cer-SERCA1a (Fig. 15A). This dose response was repeated with
4 independent experiments. As with acceptor photobleaching, we observed a rightward
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shift to the concentration dependence of PLB-SERCA FRET signifying an increased KD2
value, or a decreased affinity.
Initially, all datasets were fit by a hyperbolic function of the form y =
(FRETmax)x/(KD2 + x), with all parameters independently fit. Because mean FRETmax was
not significantly different for low and high concentrations of Tg, we concluded that
FRETmax did not change in response to changes in Tg. Therefore, this parameter was
shared in a subsequent global analysis, yielding a single FRETmax fit with independent KD2
values for each condition.
A typical plot of is shown in Fig. 15A for low (10 pM) and high (100 uM) Tg
concentrations with their corresponding fitted curves. Mean KD2 (+SE) values generated
from all data sets were then plotted against Tg concentration (Fig. 15B). A modified Hill
function shows a 78% increase in KD2 with Ca2+, with an EC50 of 350 nM and a Hill
coefficient of 0.7.

PLB Antibody Effect
In a continuation of the mean FRET experiments, we also quantified the protein
concentration dependence of FRET in the presence of the PLB antibody 2D12. AAV-293
cells expressing Cer-SERCA1a and YFP-PLB were permeabilized with 50 µg/ml saponin
for 1 min. and then washed in bath solution of composition 100 mM KCl, 5 mM NaCl, 2
mM MgCl2, 20 mM imidazole, 1 mM EGTA, and 2 mM ATP (pH 7.0), containing 10 µg/ml
2D12 PLB antibody. The E-FRET protocol was performed at 5, 30, and 120 minutes on
the same cells in the presence or absence of antibody, to determine the protein
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Figure 15: Tg effect on PLB-SERCA FRET, E-FRET. (A) As with acceptor photobleaching,
elevated Tg (red) causes a right-shifted curve compared to control (black) corresponding
to a decreased PLB-SERCA affinity with no change in the FRETmax parameter (B) The
calculated KD2 values from the example fitted curves in A are shown plotted against TG
concentration. KD2 appears to transition between two affinity states upon elevation of
Tg.
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dependence on FRET. At the 5 min. time point, no change in FRET was observed from
exposure to PLB antibody (not shown). PLB antibody greatly reduced PLB-SERCA FRET at
30 min (Fig. 16A), and to a greater extent at 120 min (Fig. 16B). At both time points,
there appears to be a reduction in the FRETmax parameter without a change in the KD2
value. More attempts are needed to determine significance.
Additionally, increased incubation time, higher antibody concentrations, and
more robust permeabilization could conceivably produce a larger effect by the PLB
antibody. Further tests are also needed to verify that a maximal effect has been
achieved before more explicit conclusions can be made. Attempts to generate a longer
time point (overnight) failed to produce usable data because of sample degradation.
Any future experiments should also include nonspecific IgG as control rather than no
antibody. However, this may suggest that the antibody may not fully dissociate PLB
from SERCA. The reduction in FRETmax would suggest an altered structure of the PLBSERCA complex.

PLB-PLB FRET
To assess PLB pentamer formation, we also quantified FRET in cells co-expressing
Cer-PLB and YFP-PLB using the E-FRET method. Cells were either exposed to 10 mM Tg
or had Ca2+ controlled to low (1 nM) and high (1 mM) concentrations with EGTA
buffered solutions as in PLB-SERCA FRET experiments described earlier. Neither Tg
exposure or changes in Ca2+ concentrations affected the FRETmax or KD1 parameters,
(Bidwell et al., 2011) and FRETmax value of 54.2 ± 0.7 is consistent with previously
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Figure 16: PLB antibody (2D12) effect on PLB-SERCA FRET. The protein dependence of
FRET in the absence (black) and presence (red) of PLB antibody after (A) 30 min and (B)
120 min incubation times.
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measured values (Hou et al., 2008; Kelly et al., 2008). This demonstrates that neither
our exposure of Tg or changes in Ca2+ concentrations alter pentamer structure or
affinity, which was expected since neither Tg or Ca2+ have been predicted to directly
interact with the PLB pentamer.
Since PLB exists in a coupled equilibrium (Fig. 4), this demonstrates that our
observed decreases in PLB-SERCA affinity by Ca2+ (Fig. 13) and Tg (Fig. 15) are not caused
my increases pentamer affinity.

With no change in PLB-PLB FRET observed, this

demonstrates that our methods of Tg exposure and control of Ca2+ concentration do not
have an effect on fluorophore stability or membrane dynamics that could globally
decrease FRET efficiency or membrane protein affinity. Therefore, the absence of PLBPLB FRET changes provides a good control experiment validating our methodology and
demonstrating that our PLB-SERCA effects are specific.

Summary
We observed a decrease in PLB-SERCA FRET in response to increases in Ca2+ and
Tg concentration. This decrease can be attributed to a reduced affinity, as observed by
an increased KD2 value. With no change in the FRETmax parameter, no change in the
distance between the fluorescent probes was observed. However, some structural
rearrangement decreasing the strength of the intermolecular contacts must account for
the decrease in affinity. This structure change is likely just not accompanied by a change
in the position of the fluorescent probes.
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We observed KD2 increases in response to increases in Ca2+ and Tg
concentrations up to a maximal level corresponding to a transition in the affinity of the
PLB-SERCA regulatory complex. We therefore believe that the Ca2+ dose response (Fig.
13B) shows PLB transitioning from binding the E2 (Ca2+ unbound) and the E1 (Ca2+
bound) conformations of SERCA. So even at saturating Ca2+ concentrations known to
fully relieve PLB inhibition of SERCA, significant PLB-SERCA binding is still observed. This
suggests that unbinding of PLB is not required for relief of PLB-SERCA inhibition.

CHAPTER VI

SERCA INTERACTION WITH TRUNCATED PHOSPHOLAMBAN

Rationale

To account for our data in the previous chapter as well as other data in the field,
we propose the Domain Displacement Model where high Ca2+ concentrations displace
the transmembrane domain of PLB to a second binding site on SERCA with no change in
the position of the cytosolic domain. To directly test this model, we need to assess
changes in position of the transmembrane which could not be accomplished in my
earlier studies. Since YFP is N-terminally linked to PLB in previous studies, we are only
able to confirm that the position of the cytosolic domain does not change in response to
Ca2+. If the transmembrane domain is displaced independently of the cytosolic domain,
the position of YFP would not change in response changes in Ca2+ concentration
To take this factor into account, we have sought to quantify FRET between
SERCA and a truncated PLB which lacks the cytosolic domain. An N-terminally linked YFP
would then be contiguous with transmembrane domain.

Therefore, if the

transmembrane domain is displaced to an alternative binding site, we expect to see a
change in our FRETmax parameter unlike with full-length PLB.
A concern with truncating PLB is that it may not then properly interact with
SERCA; therefore assessing its interaction would not be sufficient to test our hypothesis.
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Previous studies have shown that truncated PLB corresponding to residues 25-52
(Hughes et al., 1996) and 28-52 (Y Kimura et al., 1996) are capable of fully inhibiting
SERCA activity. These results provide some feasibility of our approach

Vector Construction
The sequence corresponding to residues 28-52 of canine PLB was amplified with
PCR, the product of which included BglII and HindIII restriction sites. A double digestion
and ligation were performed inserting amplified region of PLB into the eYFP-C1 vector
(Clontech) at the multiple cloning site, generating YFP-tmPLB. A complementary vector,
Cer-tmPLB, was produced by performing a double digest and ligation with YFP-tmPLB
and pmCerulean-C1 (Clontech) using the BglII and HindIII restriction sites. Both vectors
have a 7 residue spacer between the N-terminus of residues 28-52 of PLB and the
fluorescent protein, coming from the remaining sequence in the multiple cloning site.

Simulation of tmPLB FRET
Using Pymol, we estimated the anticipated distance changes produced by YFPtmPLB, compared to full-length PLB, using the PDB structures represented in Fig. 17A.
Since the positions of the fluorescent probes are unknown, some uncertainty in the
distance measurements, the estimations were made by applying distance changes to
the observed distance calculated from the FRETmax value generated by the steady-state
experiments. I first measured the distance between the N-terminus and residue 28 of
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Figure 17: FRET between YFP-tmPLB and Cer-SERCA. Simulated binding curves based on
PDB structure measurements (A) and experimentally observed binding curves (B) with
wtPLB shown shaded and dashed and tmPLB shown in solid. (A) At low calcium
concentration (black), our model predicts that decrease in FRETmax with tmPLB with a
further decrease at high calcium (red). (B) At low calcium, we observe the expected
decrease in FRETmax (black), but do not observe the expected additional decrease at
high calcium concentration (red).

78
PLB to account for the truncation. I then measured the distance between the predicted
binding pocket of helices M2/M4/M6 and the exterior position of helix M9.

Calcium Effect
FRET was quantified by the E-FRET method while Ca2+ concentration was
controlled as previously described in cells expressing Cer-SERCA1a and either YFP-PLB
(full-length) or YFP-tmPLB.

As seen previously, saturating Ca2+ (1 mM) caused a

rightward shift in the curve describing protein dependence of FRET compared to low
Ca2+ (< 1 nM) for YFP-PLB expressing cells, shown in Fig. 17B with the shaded, dashed
lines. At low Ca2+ concentration in cells expressing YFP-tmPLB, the anticipated decrease
in FRETmax to 20.1% was observed (Fig 17B, black).

However, saturating Ca2+

concentrations had no effect on the protein dependence of FRET in these cells (Fig. 17B,
red). Neither the anticipated increase in KD2 or further decrease FRETmax was observed,
suggesting that no change in the binding of YFP-tmPLB and Cer-SERCA1a occurred.

YFP-tmPLB Activity
To fully characterize the YFP-tmPLB that was used in the above experiment, we
assessed its ability to inhibit SERCA activity using the Live Cell Calcium Uptake Assay
described previously.

Expression of Cer-SERCA1a alone greatly reduces the ATP

mediated Ca2+ accumulation observed in untransfected cells. However, co-expression of
YFP-tmPLB does not attenuate the SERCA effect (Fig. 18B) as previously observed with
YFP-PLB (full-length) (Fig. 10).

Interesting this suggests that YFP-tmPLB does not

functionally regulate Cer-SERCA1a despite being able to interact.

A
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Figure 18: Characterization of tmPLB. (A) tmPLB pentamer FRET has an increased
FRETmax compared to wtPLB consistent with truncation o f the cytosolic domain. The
KD1 parameter is the same for both tmPLB and wtPLB. (B) tmPLB does not restore the
ATP dependent calcium accumulation in our in cell activity assay when co-expressed
with Cer-SERCA.
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Pentamer FRET
To further characterize YFP-tmPLB, we also assessed its ability to bind to itself by
measuring FRET between YFP-tmPLB and Cer-tmPLB using the E-FRET method described
previously. In cells expressing full length PLB tagged with YFP and Cer, we observed a
FRETmax of 53.1% (Fig. 18A, black), consistent with values obtained previously (Bidwell et
al., 2011). In cells expressing YFP-tmPLB and Cer-tmPLB, we observed an increased
FRETmax to 60.9% (Fig. 18A, red) consistent a decreased distanced produced with
removal of the cytosolic domain placing the fluorescent closer to together. The same
KD1 value was observed for both full length and truncated PLB, demonstrating that
truncation of PLB in YFP-tmPLB does not alter pentamer affinity.

Summary
A change in the FRETmax parameter was not observed when saturating Ca2+ was
added to cells expressing YFP-tmPLB and Cer-SERCA1a. Therefore, the movement of the
transmembrane domain to an alternative binding site was not observed as predicted.
YFP-tmPLB-Cer-SERCA FRET is completely unresponsive to changes in Ca2+ concentration
with neither the FRETmax nor KD2 parameter changing upon addition of saturated Ca2+.
Also, YFP-tmPLB does not appear to functionally regulate SERCA activity.

Taken

together, these observations suggest that YFP-tmPLB does not associate with SERCA as
does full-length PLB.
However, YFP-tmPLB does interact with SERCA since it expresses correctly in the
ER and undergoes FRET with Cer-SERCA1a. The FRETmax parameter is decreased to
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20.1% compared to 28.2% in full length expressing cells. This decrease is consistent with
a change in the position of YFP attached to a truncated PLB, as predicted by distance
measurements of the PDB structure. Also, the observed KD1 parameter (pentamer
affinity) is the same for both full-length and truncated PLB. These observations suggest
that YFP-tmPLB retains some binding characteristics of full-length PLB despite inability
to regulate SERCA and unresponsiveness to changes of Ca2+ concentration.
Presently, we hypothesize that steric hindrance of the fluorescent protein in YFPtmPLB prohibits functional interaction with SERCA, thereby preventing its ability to
regulate SERCA and to respond to Ca2+. Changes to the YFP-tmPLB construct may then
allow proper interaction. The planned changes and further characterization of the
current YFP-tmPLB construct are reviewed in detail in the Discussion section.

CHAPTER VII

Rationale

REAL-TIME PLB-SERCA FRET

To this point, all investigation of the PLB-SERCA interaction has utilized steadystate biochemical approaches. Because of the limitations of these studies, little is
understood about the kinetics and dynamics of this interaction.

A fundamental

question that remains is how this interaction changes over-time in response to changes
in Ca2+ concentration.

This question is all the more important considering Ca2+

concentrations change rapidly on a millisecond timescale in cardiac and slow twitch
skeletal muscle, the only PLB expressing tissues. In the case of cardiac muscle, these
changes are occurring continuously, on a beat to beat basis of the heart.
The range of Ca2+ concentration over which PLB alters the interaction with and
activity of SERCA corresponds to concentrations of a Ca2+ transient of cardiac myocyte
(100 nM – 1 µM). In other words, PLB interaction and inhibition of SERCA could
theoretically vary over the course of a single Ca2+ transient. That is if changes in binding
and inhibition occur on a fast enough timescale, which is undetermined at the present
time due to limitations of past approaches.
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Our FRET system describes a clear change in PLB-SERCA FRET in response to
elevated Ca2+.

This change occurs in the same range of Ca2+ response to assays

predicting complete dissociation, suggesting that the approaches are compatible and
detect the same change in binding.

The variations in the approaches produce a

different observable endpoint, favoring different mechanistic models. A significant
benefit of our system over all other methods is that we can detect changes in PLBSERCA binding in real time within intact cells. Therefore, our methodology has the
potential to investigate the time domain of this interaction, no matter the explicit model
of PLB-SERCA interaction.
Evidence of the timescale of PLB-SERCA binding comes from earlier work from
our lab (Robia et al., 2007). Using a FRET recovery after photobleaching approach, rapid
exchange between PLB and SERCA was observed with a time constant of 1.4 s. With this
result in combination with our steady-state experiments where Ca2+ decreases PLBSERCA FRET, we initially hypothesized that a single Ca2+ transient would cause a small
but detectable decrease in PLB-SERCA FRET. To test this hypothesis, we expressed our
fluorescent PLB and SERCA proteins in paced adult ventricular myocytes and
simultaneously measured FRET and Ca2+ concentration.

Characterization Myocyte FRET Detection
Myocyte culture and adenoviral infection are discussed earlier in the Materials
and Methods section. Localization of YFP-PLB and Cer-SERCA2a was verified with
confocal microscopy. Images show adult ventricular myocytes expressing Cer-SERCA2a
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Figure 19: Adenoviral expression of Cer-SERCA and YFP-PLB in cardiac myocytes.
Confocal images of an isolated adult rabbit ventricular myocyte expressing Cer-SERCA
and YFP-PLB. Both proteins were distributed in longitudinal streaks as well as striations.
The striations were due to localization of both proteins at the Z-line, as indicated by
counterstaining with the membrane dye FM 4-64. The overlay image shows the relative
localization of Cer-SERCA, YFP-PLB, andFM4-64. Scale bar = 10 µM.
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and YFP-PLB displaying a striated pattern of fluorescence as well as longitudinal streaks
(Fig. 19), suggesting localization in the junctional and transverse SR, respectively.
Counterstaining with the membrane dye FM 4-64 demonstrate that the t-tubule system
was largely intact after 2 days of culture. The overlay image shows that the striated
pattern of SERCA and PLB corresponds to the Z-lines of the sarcomeres. By measuring
fluorescence recovery after photobleaching, our lab has also shown that both PLB and
SERCA can diffuse across multiple sarcomeres during the course of several minutes
(Bidwell et al., 2011).
The protein dependence of FRET between PLB and SERCA in these cells was also
quantified using the E-FRET method used in the earlier steady-state experiments in AAV293 cells and described in the Materials and Methods section. FRET increased with
protein concentration towards a maximal value, consistent with the measurements
discussed previously in AAV-293 cells (Bidwell et al., 2011).

Single Calcium Transient FRET Measurements
Myocytes were infected with Cer-SERCA2a and YFP-PLB and loaded with Ca2+
indicator dye as discussed in Materials and Methods and then perfused with PC-1
medium and stimulated at a rate of .25 Hz.

Confocal time course imaging was

performed in x-t mode (linescanning) also described in Materials and Methods. Fig. 20A
shows the average of 21 con- transients obtained by line-scan mode measurements of
the indicator X-rhod-1 (black trace) normalized to diastolic Ca2+. We obtained
simultaneous measurements of YFP and Cer fluorescence with 458 nm excitation. We
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Figure 20: Quantification of calcium and FRET changes in single transients. (A) An
average of 21 consecutive calcium transients quantified by X-rhod-1 fluorescence (black)
and the corresponding PLB-SERCA FRET ratio (red) in a paced ventricular myocyte. (B) 5
µM isoproterenol increased the magnitude and decreased the width of the calcium
transient.
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did not detect a systole-to-diastole change in the normalized YFP/Cer ratio (Fig. 20A, red
trace), suggesting that FRET from Cer-SERCA to YFP-PLB is not abolished during systole.
The β-adrenergic agonist isoproterenol (5 µM) increased the amplitude and decreased
the duration of the Ca2+ transient (Fig. 20B), but FRET was still unaffected.

FRET Response to Pacing
Since individual Ca2+ transients were insufficient to produce an observable
change in PLB-SERCA FRET we hypothesized that FRET would be abolished by a larger
prolonged elevation of cytosolic Ca2+. To do so, we alternated between intervals of rest
(no stimulation) with intervals of 1-Hz pacing producing a rapid and progressive increase
in average Ca2+. While not naturally occurring, this protocol shows that our detection
method is capable of observing real-time changes in PLB-SERCA FRET in response to
rapid changes in physiological Ca2+ concentration. Essentially, we use the cellular
machinery of the myocytes rapidly alter Ca2+ concentration.
In response to Ca2+ changes of this protocol, we observed a modest reduction in
the normalized YFP/Cer ratio with rapid pacing apparent in the absence (Fig. 21A) or
presence (Fig. 21B) of 5 µM isoproterenol. Fig. 21C/D (black) shows the mean cytosolic
Ca2+ elevation for control (n = 6 cells) and after the addition of isoproterenol (n = 4 cells)
normalized to resting Ca2+, and the corresponding mean YFP/Cer ratio is shown in red.
During pacing intervals, the mean cytosolic Ca2+ was significantly elevated when
compared with rest, both before (p < 0.01) and after (p < 0.01) isoproterenol. FRET was
also significantly decreased when compared with rest, both before (p < 0.05) and after
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Figure 21: Quantification of calcium and FRET changes by alternating pacing. (A)
Prolonged elevations of Ca2+ (black) were achieved with intervals of rapid (1 Hz) pacing
after periods of rest (no stimulation). A modest decrease in FRET (red) was observed
during rapid pacing. The blue lines represent the Ca2+ and FRET traces smoothed by 5
second adjacent averaging. (B) As in A, after 5 µM isoproterenol, a small decrease in
FRET (red) was observed during rapid pacing. (C) Averaging multiple experiments
showed that rapid pacing increased mean [Ca2+], with a larger increase observed after
addition of 5 µM isoproterenol. (D) Averaging multiple experiments showed that rapid
pacing decreased the mean YFP/Cer ratio, and this decrease was larger after addition of
5 µM isoproterenol. The first, second, and third pacing intervals are marked “a, b, c.”
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(p < 0.01) isoproterenol. Overall, the data are consistent with a small decrease in FRET
during intervals of rapid pacing.

FRET Response to Calcium Changes in Heterologous Cells
With the time resolution of Fig. 21, we can estimate that the change in FRET
occurs within 2 seconds of elevation of the Ca2+. However, this is a much longer than
the time course of a single Ca2+ transient.

We therefore cannot conclude if the

rest/pace protocol produced a change in FRET due to a higher Ca2+ concentration, a
more prolonged Ca2+ elevation, or both.
To test these possibilities, we set out to measure the time response of PLBSERCA FRET to elevations of Ca2+ in AAV-293. Cells expressing Cer-SERCA and YFP-PLB
were loaded with X-Rhod-1 as in the myocytes, and then bathed in PBS containing 1 mM
EGTA and ionomycin. Image acquisition of E-FRET and Ca2+ concentration every 10 s
was started at this low concentration. After 1 min of acquisition to achieve baseline
signals, PBS containing 2 mM Ca2+ added and acquisition continued. Fig. 22 shows that
increases in Ca2+ concentration appear to directly coincide with decreases in FRET signal,
suggesting a rapid response. However, time resolution of this approach is insufficient to
clearly determine the time course of the Ca2+ action. Further experimentation with
faster time resolution is needed, but indicates that this methodology clearly detects
changes in FRET in response to Ca2+ over time.
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Figure 22: Time course of calcium effect on PLB-SERCA FRET. In AAV-293 cells bathed in
10 µM ionophore, addition of 1 mM Ca2+ to the bath solution increases intracellular Ca2+
concentrations estimated by average X-Rhod-1 fluorescence (black). Average PLBSERCA FRET (red) decreases rapidly in response to the elevated Ca2+.
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Summary
We observed no change in PLB-SERCA FRET in response to the individual Ca2+
transients of paced cardiac myocytes. Even with the enhancement of these transients
from the exposure to β-adrenergic stimulation, no change could be observed. However,
we did observe a small (2%) decrease in FRET in response to intervals of prolonged rapid
pacing and rest, which produced relatively higher and more prolonged elevations of
cytosolic Ca2+ compared to individual transients. While not a physiologic pacing pattern,
this protocol demonstrates the capability of our approach in detecting real-time
changes in FRET in response to physiological changes in Ca2+ concentration. We must
now attempt to determine the specific time domain of Ca2+ action on PLB-SERCA FRET.

CHAPTER VIII
DISCUSSION

Global versus Single Molecule Effects

One of the ultimate goals of this research is to understand the mechanism of PLB
inhibition of SERCA with respect to how individual molecules interact and function.
However, our work, as well as the studies that have preceded it, is attempting to do so
by making global assessments of a large population of molecules. While we attempt to
favor the existence of a particular conformation of SERCA in our steady-state
measurements, we ultimately only achieve an equilibrium shift in a distribution of
several conformations. In our real-time FRET measurements, we are not observing
synchronous changes in all PLB-SERCA interactions, so at any given point in time we are
observing several interacting states. Therefore, any given measurement of the PLBSERCA interaction is a composite of many interacting molecules from which we attempt
to deduce information on the interaction of individual molecules. This is not a critique
of our approach given the inherent difficulty of making single molecule measurements,
but merely an important consideration necessary to put our results, and the results of
others, in the proper perspective.
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Steady State FRET
We have used FRET to measure the interaction between fluorescently tagged
PLB and SERCA in cells under conditions that favor particular structural conformations of
SERCA. At low Ca2+ concentrations that favor the E2 SERCA state, we have observed
that PLB interacts with SERCA in a protein dependent manner consistent with our
previous use of this approach (Ha et al., 2011; Hou & Robia, 2010; Hou et al., 2008; Kelly
et al., 2008; Song et al., 2011). This observation is also consistent with both the
Dissociation and Subunit Models of PLB-SERCA regulation, since both predict that PLB
interacts with the E2 conformation with high affinity.
When Ca2+ was elevated to saturating concentrations favoring the E1
conformation, we observed that PLB-SERCA FRET was decreased, but not completely
abolished (Fig. 13). The decreased FRET can be explained as a reduced affinity between
PLB and SERCA (increased KD2) without a change in the structure of the regulatory
complex (no FRETmax change).

While binding is decreased at any given protein

concentration, significant levels of binding are detected at saturating concentrations of
Ca2+. This is inconsistent with the Dissociation Model where FRET would be predicted to
be completely abolished. In theoretical terms, the mutually exclusive binding described
by the Dissociation Model predicts a KD2 value that approaches infinity with increasing
Ca2+ concentrations. KD2 certainly would not achieve a maximal level as we observed.
Under physiological constraints, an increase in the KD2 value by a few orders of
magnitude at millimolar Ca2+ would effectively correspond to the Dissociation Model.
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However, the much lower 40% increase in KD2 would not be consistent with complete
dissociation of PLB and SERCA at physiological conditions Ca2+ concentrations.
One might argue detection of PLB-SERCA binding in the presence of Ca2+ is an
artifact of our approach. The high concentrations of proteins in the membrane will
place non-interacting proteins in close enough proximity to undergo energy transfer. It
is certainly possible that unbound proteins will undergo FRET.

However, in a

competition assay using unlabeled PLB, we currently estimate FRET between unbound
membrane proteins or “non-specific FRET” around at most 4%. This is clearly much
lower than the 28% FRET observed with our assay. Furthermore, we have shown that
the estimated distance between the probes can be specifically altered and that this
distance is consistent with known structure of SERCA(Hou & Robia, 2010; Kelly et al.,
2008; Song et al., 2011). These observations suggest that FRET is not likely caused by
aggregation of the fluorescent probes which has been suggested to skew FRET
measurements (Chen et al., 2006).
These results are more in line with the Subunit Model and the previous FRET
studies where high levels of PLB-SERCA binding are detected even in the presence of
Ca2+ (Mueller et al., 2004). Mueller et al observed only a minimal decrease in FRET in
the presence of Ca2+ at the highest protein concentrations rather over the full range of
concentration as was observed with our approach. This decrease in was consistent with
a small structure change of the regulatory complex corresponding to approximately a 1
Å movement that was not detected with our approach. Unlike our results, Mueller et al
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did not observe a change in PLB-SERCA affinity, but it is possible that their method did
not assess interaction at sufficiently low protein concentrations where the affinity effect
would be observed. Although we observed no change in our distance measurements, a
1 Å movement is within the error of our method. The larger size and rotational mobility
of the fluorescent proteins used in our method may mask the subtle change Mueller et
al observed using small, covalently attached fluorophores.
Just like Ca2+, the presence of the SERCA inhibitor Tg has been shown to
completely abolish PLB-SERCA crosslinking (Chen et al., 2006, 2005) but only slightly
diminish FRET in our system. Like Ca2+, we observed that Tg reduced PLB-SERCA affinity
(increased KD2) with no change in the structure of the complex (no change in FRETmax)
(Fig. 15). While assessing the ability of PLB and SERCA to interact in the presence of Tg
does not assist in the modeling the PLB-SERCA mechanism, it does aid in the validation
of our FRET approach. Because Tg is membrane permeable, its application is a more
straight forward protocol as compared to Ca2+ which requires saponin permeabilization
to introduce artificial cytosolic solutions. Our observation of a lack of complete PLBSERCA dissociation at elevated Ca2+ concentrations is likely not due to insufficient
permeabilization or inappropriate solutions since Tg produced a comparable effect.
Early proteolysis studies displayed no difference in the fragmentation patterns of
SERCA at low Ca2+ concentrations and in the presence of Tg (Sagara & Inesi, 1991). This
observation was thought to indicate that SERCA bound by Tg was comparable to the E2
Ca2+ free conformation. Tg was then used to stabilize SERCA in what was assumed to be
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the E2 conformation for some of the first high resolution crystallographic studies
(Danko, Yamasaki, Daiho, Suzuki, & Toyoshima, 2001; Toyoshima & Nomura, 2002).
However, current consensus suggests that SERCA bound by Tg is not representative of
the E2 conformation, and alternative crystal structures of the E2 conformation have
been developed in the absence of Tg. Our Tg dose response curve (Fig. 15B), showing
two PLB affinity states, also suggests that SERCA bound by Tg is a structural
conformation distinct from the E2 Ca2+ free conformation.

We have named this

conformation “E2-Tg” for its similarity to, yet distinct from, the E2 Ca2+ free
conformation. The E2 and E2-Tg conformations likely have similar cytosolic orientation
exposure the same cleavage sites, yielding the same banding pattern. They however
differ greatly in the transmembrane region where the strength of the PLB-SERCA
interaction is likely dictated.
Both the Ca2+ and Tg effects on our FRET measurements occur in the same range
of concentrations as the crosslinking approach.

This similarity suggests that both

approaches are likely detecting the same change in PLB-SERCA binding, but are just
detected by a different signal.

This consistency helps validates our overall FRET

approach showing that the changes we observe are not unique to our system.
Because of the predicted large structure changes in the cytosolic headpiece
between the E1 and E2 conformations of SERCA, we thought it likely that this could
generate a large structural change in cytosolic region of the PLB regulatory complex.
However, we did not observe a change in the FRETmax parameter, indicating no change
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in the position of the fluorescent probes attached to the N-terminus of both PLB and
SERCA, loci that would be thought to move apart. During the E2 to E1 transition, there
could be a coordinated movement of both fluorescent probes that does not change the
distance between them. On the other hand several studies have suggested that the
movement of the SERCA headpiece is much smaller than initially predicted (Jensen et
al., 2006; Sørensen et al., 2004; Winters et al., 2008). These more subtle changes could
also explain the lack of a FRETmax change in our experiments
Under no conditions were we able to detect complete loss of PLB-SERCA FRET.
In particular, we observed a high degree of FRET between PLB and SERCA under
conditions that favor particular conformation (E1 and E2-Tg) that have been shown to
block chemical crosslinking. These crosslinking observations are the backbone of the
Dissociation Model. In contrast, our evidence suggests the high likelihood that PLB can
bind all conformations of SERCA, although with varying affinities. This conclusion is
summarized in Fig. 23 showing the coupled equilibrium between PLB pentamer,
monomer, and monomer bound to various conformations of SERCA with independent
dissociation constants.
While we have not performed an exhaustive investigation into all possible
conformations, we have observed a high level of FRET even at saturating Ca2+
concentrations known to fully relieve PLB inhibition of SERCA. This suggests that PLB
can remain bound throughout the reaction cycle SERCA, implying ability to bind all
conformations. We therefore conclude that unbinding of PLB is not required for relief
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Figure 23: Summary of PLB binding. PLB monomer can bind to itself forming a pentamer
or bind to SERCA in any conformation, however doing so with varying affinity.
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of PLB-SERCA inhibition. This is not without precedence since it phosphorylation of PLB
has been suggested to relieve inhibition without causing dissociation of the regulatory
complex.

Alternative Binding Site
In our Ca2+ dose curve, we detect two different modes PLB-SERCA binding. The
change in binding states could describe a simple structural reorientation merely
decreasing the strength of the intermolecular contacts of PLB at the same location on
SERCA. On the other hand, the detected change could be described by displacement of
PLB to an alternative binding site. Crosslinking by the Jones lab (Chen et al., 2007, 2006,
2005; Jones et al., 2002) and mutagenesis studies by the MacLennan lab (Y Kimura et al.,
1996; MacLennan, Kimura, & Toyofuku, 1998; Toyofuku et al., 1993) provide good
evidence for a site of interaction that also likely facilitates inhibition. To this point, there
has been no direct evidence of an alternative binding site for PLB on SERCA.
However, some evidence for an alternative site comes from X-ray
crystallography studies predicting the binding of homologous proteins, NKA and PLM, at
a more exterior location on helix M9 (Fig. 7) (Shinoda et al., 2009). While this provides
sufficient evidence to hypothesize the existence of two distinct PLB binding sites on
SERCA, it certainly does not confirm it. This exterior binding site could be unique to the
PLM-NKA complex and could be the sole site of interaction. However, it seems unlikely
that proteins with such similarities would have vastly different interactions and
inhibitory mechanisms. The more likely explanation is that this detected interaction is
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just an artifact of crystallization and does not describe the actual functional site of
interaction between NKA and PLM.
One could argue that interaction at the Ca2+ binding site is the only important
interaction. The displacement of PLB to an alternative binding site and the complete
displacement of PLB from SERCA are not significantly different, since both describe a
movement out of the functional site. However, this difference would greatly alter the
dynamics of the system. Binding of PLB to an alternative site would enhance the on-rate
of PLB by keeping it in close proximity to the functional site. In other words, its effective
concentration would be much higher.
The Jones group has questioned our proposal of an alternative binding site for
PLB since their crosslinking studies have found no evidence of a second site (Akin &
Jones, 2012). However, they have yet to look for enhancement of crosslinking at an
exterior site by Ca2+. Their evidence is the use of crosslinkers varying in distance from 015 Å which have not shown differential binding. However, movement of PLB by 20 Å
places it just outside the predicted binding groove and our exterior site corresponds to a
movement of 40 Å.
The role of this potential binding site is unclear and could be merely serve as a
place holder to enhance on and off rates of PLB. The importance as a place holder
should not be underestimated, because variations in the ability to bind the alternative
site will likely have a tremendous impact on how PLB interacts with the functional site.
Changes at the alternative site would alter the equilibrium binding producing a different
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stead-state interaction and inhibition. Also, there would be a significant impact on the
dynamics of inhibition since the on and off rates at the functional site could be altered.
Besides affecting how PLB interacts at the primary functional site, the secondary site
itself may have the ability to functionally regulate SERCA. Whatever the purpose of the
secondary site, the next step of the investigation is determining whether it exists,
followed by a characterization of the site.

We could then attempt to alter the

interaction at the secondary site and then determine how the ability of PLB to regulate
SERCA is changed. If this secondary site is confirmed to exist, an intriguing question that
results is how binding at one site excludes binding at the other site, since a strict
PLB:SERCA stoichiometry of 1:1 is observed.

Proposed Model of PLB Inhibition
We have attempted to reconcile the findings of others to account for the
limitations of all approaches and develop a model that is consistent with all data in the
field. We propose that high Ca2+ displaces the transmembrane domain of PLB to an
alternative, lower affinity binding site on SERCA, with no change in the position of the
cytosolic domain. We have termed this the “Domain Displacement Model.” In other
words, binding to the E1 and E2 conformations of SERCA differs only in the position and
affinity of the transmembrane domain of PLB. This accounts for our data showing that
Ca2+ reduces the affinity of PLB for SERCA. This also explains why our data and FRET
measurements from Mueller et al detect no or only a small change in the position of the
cytosolic domain where the fluorophores are attached.

Movement of the
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transmembrane domain to a more exterior site would also explain why Jones sees no
crosslinking at high Ca2+. The differences between the models are summarized in Fig.
24.
We started to directly test this model by measuring FRET between SERCA and a
truncated PLB lacking the cytosolic domain which would assess the position of the
transmembrane domain of PLB in association with SERCA. Our YFP-tmPLB construct
expresses normally and interacts with itself and SERCA at low Ca2+ concentrations as
anticipated. However, FRET between Cer-SERCA and YFP-tmPLB is unresponsive to Ca2+
and does not appear to regulate SERCA. So while YFP-tmPLB retains some of the
binding characteristics of full-length PLB, clear differences are apparent. We suspect
that steric barriers created by the membrane and SERCA may be preventing proper
localization, and therefore function, of YFP-tmPLB. Further experimentation is needed
to address these results including additional characterization of the YFP-tmPLB
construct as well as development of alternative constructs. While this construct did not
function as initially hypothesized, it does provide evidence for a non-functional PLBSERCA interaction. Assessment of how this interaction occurs without inhibition of
SERCA could also be critical to our understanding of the PLB-SERCA mechanism.
Earlier studies showing the ability of truncated PLB to inhibit SERCA were
performed at a high excess of PLB peptide (Hughes et al., 1996; Y Kimura et al., 1996),
with no assessment of its interaction or affinity. The conclusions from these studies that
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Figure 24: Models of PLB-SERCA binding. The previously discussed Dissociation and
Subunit Models are shown in comparison to our proposed Domain Displacement Model.
We propose that elevated calcium concentration displaces the transmembrane domain
of PLB to alternative SERCA binding site of lower affinity, with no change in the binding
location of the cytosolic domain.
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fully inhibit SERCA may have been incorrect, and even if the suspected steric issues with
YFP-tmPLB are corrected, full inhibition may not be achieved.

Effects of Pacing on Myocyte FRET
Irrespective of the mechanistic model of inhibition, it is critical to understand
how the PLB-SERCA interaction changes over time. Because the ability of PLB to inhibit
SERCA varies with respect to Ca2+ concentration, the level of PLB inhibition will not be
constant in cardiac myocytes. Not only is Ca2+ concentration perpetually changing over
the course of individual Ca2+ transients; basal concentrations can also be altered by
various stimuli. To date however, all measurements of the ability of PLB to bind to and
regulate SERCA have been taken at equilibrium. So we have no comprehension of how
rapidly the PLB-SERCA binding changes in response to changes in Ca2+ concentration.
Since Ca2+ concentration changes rapidly and constantly in the physiological
environment of PLB and SERCA, we must assess the dynamics of the PLB-SERCA
interaction to fully understand its physiologic function. Unlike previous studies, our
FRET approach is capable of assessing PLB-SERCA binding in real time. We are therefore
uniquely poised to address this critical question.
We detected no change in PLB-SERCA FRET over the course of a single Ca2+
transient. Only by using a non-physiological rest/pace protocol that produced higher
and more sustained Ca2+ increases were we able to observe changes in FRET. These
observations were somewhat expected since our steady-state experiments predict at
most a small 3% change in FRET in response to increases in Ca2+ concentration. These
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observations could be explained in a few ways. It might indicate that there are two
significant pools of SERCA, PLB unbound (active) and PLB bound (inactive). This PLB
unbound and active pool of SERCA is sufficient to move the Ca2+ of a typical single
transient back into the SR. Only when Ca2+ concentrations are elevated during our
rest/pace protocol, and additional SERCA activity is required, is PLB inhibition relieved
and a decrease in FRET observed. However, these distinct bound and unbound pools
are inconsistent with several studies that have suggested that SERCA is nearly 100%
bound by PLB under basal conditions in larger mammals (Waggoner et al., 2009). Our
observed pacing effects are more consistent with the scenario where dissociation of PLB
from SERCA is not required for the relief of inhibition. The SERCA activity necessary over
the course of a Ca2+ transient could then be achieved without a significant change in
PLB-SERCA interaction.

Only when Ca2+ concentrations are elevated during our

rest/pace protocol is the PLB-SERCA affinity shifted sufficiently to generate a decrease in
FRET.
Lack of an observable change in FRET does not indicate an absence of change in
PLB-SERCA binding over the course of a single Ca2+ transient. Certainly, a change in
binding can occur that would not significantly alter FRET. As discussed previously
concerning an alternative binding site on SERCA, the position of the fluorescent protein
at the N-terminus of PLB does not allow detection of a change in the position of the
transmembrane domain. If applying our proposed Domain Displacement Model of PLB
interaction (Fig. 24), one could envision that the transmembrane domain of PLB
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transitions rapidly between the two binding sites in response to changes in Ca2+, with no
change in the position of the cytosolic domain. A YFP-tmPLB that could successfully
produce the anticipated response to Ca2+ would be a useful tool to investigate potential
changes in the position of the transmembrane domain in response to Ca2+ transients.
However, if successful, this type of experiment should be viewed with caution since the
cytosolic domain could facilitate any transition. Its absence could certainly then affect
the rates of transition.

Future Directions
While our proposed model of PLB inhibition of SERCA is a plausible explanation
that could integrate our data with previously published research, we lack sufficient
support for this model. We must first determine whether the secondary site exists and
whether Ca2+ can cause transition to this binding site. The FRET experiments with the
truncated PLB could be capable of showing both, but the initial experiments have not
produced the anticipated results. We suspect that steric hindrance of the fluorescent
protein may be preventing proper localization of tmPLB. If correct, tmPLB lacking YFP
should then be able to properly interact and inhibit SERCA. This could be tested by
developing an unlabeled peptide consisting of only residues 28-52 of PLB probing the
ability of this peptide to inhibit SERCA. If unlabeled tmPLB is not functional, this would
directly challenge previous observations that the transmembrane domain in isolation is
fully capable of inhibiting SERCA (Hughes et al., 1996; Y Kimura et al., 1996). Though
this seems unlikely since an analogous protein sarcolipin, which lacks a comparable
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cytosolic domain, is able to inhibit SERCA activity (Bhupathy et al., 2007; Periasamy,
Bhupathy, & Babu, 2008).
Also, if FRET between YFP-tmPLB and Cer-SERCA is diminished by expression of
unlabeled PLB or tmPLB (if functional), this would demonstrate binding competition.
This would indicate that the YFP-tmPLB interaction with SERCA is not anomalous and
not an artifact of our approach.

Furthermore, it could indicate that YFP-tmPLB

preferentially interacts at the secondary, non-inhibitory site.
If steric hindrance of YFP is the contributing factor preventing ability of YFPtmPLB to inhibit SERCA, modifications to the construct could relieve the steric block.
Specifically, the 7 amino acid linker between tmPLB and YFP could be lengthened so that
YFP could be positioned further away from the membrane. Use of the shortest linker
that is able to allow proper inhibition of SERCA would be ideal. This would alleviate
some potential variability in FRET measurements produced flexibility and movement of
the fluorescent protein. In order to be versatile, the additional linker sequence should
be comprised of simple amino acids such as glycines. Use of prolines could also be
considered since they may provide some stability to the linker, thereby reducing
flexibility and potential variability of FRET measurements.
Rather than developing PLB variants to investigate the potential secondary site,
we could also make modified SERCA proteins. We could make targeted mutations of
helix M9, in an attempt to disrupt binding at the proposed secondary site. Diminished
binding at the secondary site would be observed as a further lowering of affinity at high
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Ca2+ concentrations compared to non-mutated SERCA. Furthermore, if PLB exists in
equilibrium between the two sites, decreased affinity at the secondary site could
enhance affinity at the primary functional site presenting as increased affinity at low
Ca2+ concentrations and enhanced inhibition by PLB.
SERCA3 could provide for an interesting model for the investigation of the PLBSERCA mechanism. While PLB has been clearly shown to have no effect on the activity
of SERCA3 in functional assays (Y Kimura et al., 1996; Toyofuku et al., 1994), the ability
of PLB to bind SERCA3 has not been determined.

Measuring FRET between YFP-PLB

and Cer-SERCA3 might provide a unique perspective, potentially showing a noninhibitory binding interaction. Perhaps this interaction would be unresponsive to Ca2+
suggesting PLB can only bind the secondary, non-inhibitory site.
Our FRET results and proposed model would greatly benefit from support of
alternative approaches. While crosslinking results to date have directly contrasted our
findings, we believe this approach could be modified to show binding at a secondary
site. Jones et al have not found evidence of a secondary binding site, but this could be
attributed to the fact that they have yet to directly test the existence of an alternative
binding site. All studies have targeted residues in the suspected binding pocket of
M2/M4/M6 on SERCA. Binding at a more exterior position such as M9 would go
undetected.

Therefore, use of untargeted reagents such as benzophenone and

glutaraldehyde which bind carbon and amine groups may successfully crosslink PLB to
SERCA at a position outside the proposed binding pocket under saturating Ca2+
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conditions. Additionally, SERCA mutants could be generated that introduce cysteines or
lysines on helix M9 to perform so that the site directed crosslinking protocols of the
Jones lab could be used.

Concluding Remarks
In this dissertation, I have shown our evidence that suggests that dissociation of
PLB from SERCA is not required for relief of inhibition. To account for this observation
as well as previous data from other labs, I have also described the Domain Displacement
Model of regulation. Furthermore, I have also demonstrated the ability to detect PLBSERCA binding in real-time in response to physiological changes of Ca2+ concentration.
Doing so, I have shown evidence that single Ca2+ transients of paced cardiac myocytes
do not produce an observable change in PLB-SERCA binding.

The results and

methodology presented here have added to our understanding of PLB-SERCA regulation
and continuation of this research is poised to answer critical questions in the field.
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